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Huang, Wanfeng. Ph.D., Purdue University, December 2016. Concurrent Detection and Isolation of Cellular and Molecular Biomarkers. Major Professor: Çağrı Savran, School of Mechanical Engineering.    Detection of cancer markers such as protein biomolecules and cancer cells in bodily 
fluids is of great importance in early diagnosis, prognosis as well as evaluation of therapy 
efficacy. Numerous devices have been developed for detecting either cellular or molecular 
targets, however there has not yet been a system that can simultaneously detect both 
cellular and molecular targets effectively. Molecule and cell-based assays are important 
because each type of target can tell a different story about the state of the disease and the 
two types of information can potentially be combined and/or compared for more accurate 
biological or clinical assessments. Therefore, the primary goal of the thesis is to develop a 
system that can simultaneously measure both cellular and molecular biomarkers from one 
and the same sample. With its high sensitivity and high-throughput capability, this system 
can capture rare cells such as circulating tumor cells (CTCs) from human bodily fluids (e.g. 
blood, ascites). Moreover, the system enables post-detection analysis of captured targets 
and can be compatible with established screening tools. In this thesis two generations of 
the system have been developed to achieve these goals. 
xiv 
 
The first-generation system is based on a single-layer fluidic chamber. Free magnetic 
beads conjugated with antibodies against a specific antigen are used to isolate both free 
molecules and whole cells overexpressing an antigen. The captured cells and molecules are 
quantitatively analyzed together on the same device surface using fluorescent microscopy. 
The system was first numerically modeled, and then experimentally characterized by 
simultaneously detecting free folate receptor (FR), and an FR+ cancer cell line (KB) that 
were added into cell culture medium with known number. This system was further 
validated by detecting KB cells and FR spiked into healthy human blood to simulate 
detection of CTCs and protein biomarkers present in cancer patient blood. The potential of 
this approach in clinical diagnostics was also demonstrated by detecting both FR+ cells 
and FR in an ascites sample obtained from an ovarian cancer patient. 
The second-generation system employs a similar detection strategy but integrates a 
micro-aperture chip into the fluidic chamber to sort cells and molecules (including free 
beads) into different layers based on their sizes, which significantly reduces mutual 
interference and improves detection efficiency including detection yield and repeatability. 
Moreover, large number of beads can be used to further increase cell detection yield. The 
system was first characterized by detecting rare cells spiked in both cell culture medium 
and health human blood and applied for CTC detection from cancer patients’ blood samples. 
Then the system was further developed for separation and simultaneous detection of both 
model molecular and cellular prostate cancer markers (namely the prostate-specific 
membrane antigen (PSMA), LNCaP cells) from both culture medium and blood. 
Finally, a post-detection application was demonstrated by culturing the cells that were 
detected and retrieved by our second-generation system. Future work will be focused on 
xv 
 
gene sequencing of captured rare cells, screening of cancer patient blood samples for dual 
detection of molecules as well as cells, and integration of novel capture ligands. 
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CHAPTER 1. INTRODUCTION 
1.1 Motivation 
Detection of biomarkers is of great significance in numerous biomedical fields including 
diagnosis, prognosis, therapeutic evaluation, as well as in pharmacodynamics studies and 
cell identification [1-3]. Biomarkers include a wide variety of molecules such as small 
analytes (e.g. hormones, metabolites, etc.), larger biomolecules (e.g. DNA/RNA, proteins, 
etc.) as well as cells themselves [4-9]. It has been shown that biomarkers have numerous 
advantages and offer great potential, however, barriers and limitations have reduced their 
real-life utility [1, 2, 10-12]. Inter-individual variability, reliability, sensitivity and 
specificity have led to measurement deviations which become exacerbated when only a 
single biomarker is used. As a result, multiple platforms are often employed to perform 
numerous biomarker tests, often at great expense, in order to provide sufficient and reliable 
information for patient evaluation [13-16]. 
 In cancer research and diagnostics, cells and proteins are the most common entities to 
be detected [17-20]. During the past decade, circulating tumor cells (CTCs) have been 
extensively studied and validated as a prognostic tool in prostate cancer [21, 22]. CTCs are 
shed from both primary and metastatic tumors and circulate in the blood of cancer patients. 
CTCs have the potential to serve as indicators of metastatic disease and possibly recurrence 
after surgery in some tumor types [4-7, 23]. They are very scarce (as few as 1 or less per 
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mL of blood sample as opposed to some 10 million normal white blood cells and 100 
million red blood cells per 1 mL of blood) thus large sample volume (~7.5 mL) is necessary 
for reliable analysis.  
On the other hand, protein biomarkers in serum can reveal information about the onset 
and progression of many diseases ranging from heart failure to cancers [8, 9]. Serum 
proteins such as prostate specific antigen (PSA), epidermal growth factor receptor (EGFR) 
and carcinoembryonic antigen (CEA) have been approved by US Food and Drug 
Administration (FDA) as cancer biomarkers [9]. Meanwhile, continuous efforts are being 
placed on searching novel protein biomarkers. For example, many studies show that folate 
receptor (FR) or folate binding protein (FBP), a glycosylphosphatidylinositol-linked 
protein, is a biomarker for several epithelial malignancies [24-26]. It has been shown that 
ovarian cancer patients have elevated serum levels of FR alpha, which is over-expressed 
on the surfaces of malignant cells which can eventually shed into the blood [27].  
Despite the advances in detecting molecules and cells, to our best knowledge, there has 
not been a system capable of effectively detecting both of these markers at the same time 
and from the same sample. Although it is possible to adapt some molecular detection 
platforms to detect whole cells, and vice versa, most platforms are optimized and 
configured for detection of either molecules or cells but not both. Often, multiple devices 
are used to perform each test separately, at different times, and/or with different samples. 
For example, Pierga et al. investigated the prognostic and predictive value of CTCs in 
chemotherapy for metastatic breast cancer patient by means of a comparison with serum 
tumor markers (e.g. CEA, CA15-3 and lactate dehydrogenase) [28]. Hou et al. evaluated 
both CTCs and serological cell death biomarkers as blood assays of small lung cancer 
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patients undergoing chemotherapy [29]. Davis et al. studied the correlation between CTCs 
in peripheral blood samples from prostate cancer patients and their serum levels of prostate 
specific antigen [30]. In their studies, patient samples (e.g. blood, ascites) were first 
collected separately and then screened by multiple tools such as enzyme-linked 
immunosorbent assays (ELISA) to quantify molecular markers and CellSearch system to 
quantify the CTCs. A major and obvious limitation in performing molecular and cellular 
analyses at different times, different samples and different platforms is the variation among 
samples themselves and/or the experimental conditions such as temperature, incubation 
period, chemical reagents used to preprocess the sample by each different platform and so 
on [28-30]. 
This thesis study aims to develop a system capable of concurrently detecting both cellular 
and molecular markers from one sample. In addition to overcoming the shortcomings 
discussed in previous paragraph, this system has the capability to analyze large volumes of 
sample to efficiently capture rare cells (e.g. CTCs) and biomolecules (e.g. serum cancer 
markers). We expect that detecting both cells and molecules should provide more complete 
information (e.g. regarding tumor stage, metastasis, treatment evaluation) than detecting 
only proteins or only cells, and potentially enable newer and more useful analyses. Finally, 
the new system can retrieve captured cells and molecules for subsequent analysis, which 
can further lead to the discovery of new mutations and expand our understanding of cancer 
biology via DNA/RNA sequencing [19, 31, 32]. 
1.2 Current Systems for Cell Detection 
Isolating cells from biological fluids has always been important for a number of fields 
such as cell biology, physiology, medicine and pathology [33-36]. For example, 
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detection/isolation of circulating tumor cells (CTCs) has the potential for prediction of 
treatment efficacy and possibly early detection of cancer, and hence has received 
significant attention in recent years [4-7]. 
Cell sorting techniques are routinely applied to separate cells of interest from 
heterogeneous suspensions [37]. There are many methods currently available for rare cell 
detection and isolation. Examples of some commonly seen methods and systems will be 
described and discussed in the following sections. 
1.2.1 Fluorescence-activated Cell Sorting (FACS) 
Fluorescence-activated cell sorters (FACS), e.g. flow cytometry (Figure 1.1), are widely 
used in biomedical research and clinical diagnostics. These tools greatly facilitate the study 
of both physical properties (e.g., size, shape) and biochemical properties (e.g., cell cycle 
distribution, DNA contents) of biological particles such as cells. Information regarding the 
cells that pass through the device is acquired optically in a nondestructive and quantitative 
manner. After signal-reading, the cells of interest are immediately labeled with an electrical 
polarization that is the opposite of that of the other cells, then the labelled cells are deflected 
into a collection zone using an electrical force. This method can automatically sort out and 
analyze cells of interest. However, because of the serial nature of its operation, FACS is 
limited to a comparatively low throughput especially when a large sample volume (e.g. 7.5 
mL) is processed [37, 38]. FACS is most effective for analyzing thousands to millions of 
cells in a mL (as opposed to rare cells that present themselves much more scarcely: 1 cell 
per mL or less). This costly system is quite complicated and prone to practical problems 




Figure 1.1. Schematic of Fluorescence-activated cell sorting [40]. 
1.2.2 Magnetically Activated Cell Sorting (MACS) 
The MACS method separates cells by incubating them with magnetic particles coated 
with antibodies against a particular surface antigen. Cells expressing this antigen attach to 
the magnetic nanoparticles. Following that the cell suspension is transferred to a column 
placed in a magnetic field. In this step, the cells conjugated with the magnetic particles as 
well as the particles that have not bound to any cells stay on the column, while other cells 
(not expressing the antigen) flow through. With this method, the cells can be sorted out 
with respect to the particular antigen. This simple method is used for capturing of the cells 
but not their detection. Hence, once the cells are sorted, they are mostly used in conjunction 
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with a detection platform such as FACS. The manual MACS columns are commercially 
available by providers such as Miltenyi Biotec. 
Researchers have also developed sophisticated and advanced systems based on the 
MACS principle. Professor Soh's group at UC Santa Barbara reported a magnetically 
activated cell sorter (MACS), which makes use of microfluidics technology to sort multiple 
types of target cells in a continuous-flow manner [41]. They used the MACS device to 
purify 2 types of target cells, which had been labeled via target-specific affinity reagents 
with 2 different magnetic tags with distinct saturation magnetization and size (Figure 1.2). 
The device was engineered so that the combined effects of the hydrodynamic force 
produced by the laminar flow and the magnetophoretic force produced by the patterned 
ferromagnetic structures within the microchannel result in the selective purification of the 
differentially labeled target cells into multiple independent outlets [41].  
This sophisticated system has well defined requirements for the size, shape and 
magnetization of the magnetic tags to achieve a balance between the functional magnetic 
force and the fluidic drag force. These requirements increase the overall complexity and 
the fabrication cost. Also, large sample volume (e.g. 7.5 mL of patient blood) is often 
necessary for rare cell detection. However, the volumetric flow rate that can be achieved 





Figure 1.2. Schematic of magnetic-activated cell sorting [41]. 
1.2.3 Other Microfluidic Methods  
A number of groups have developed cell sorting systems that employ microfluidics in 
various forms. Here we only focus on the system that we believe is the most advanced 
system developed so far. Professor Toner's group developed a strategy that combines 
microfluidics for rare cell handling while incorporating the benefits of magnetic-based cell 
sorting (e.g. high sensitivity and purity, easy to be operated) [7]. After magnetically 
labeling cells in whole blood, their capture platform integrates three sequential microfluidic 
components (Figure 1.3) within a single automated system: (i) separating nucleated cells, 
including CTCs and white blood cells (WBCs), from red blood cells (RBCs) and platelets 
using deterministic lateral displacement; (ii) alignment of nucleated cells into a single file 
within a microfluidic channel using inertial focusing; and (iii) deflection of magnetically 




Figure 1.3. Schematic of inertial focusing for cell separation [7]. 
The advantage of this platform is that the three integrated microfluidic functions replace 
bulk RBC lysis and/or centrifugation, hydrodynamic sheath flow in flow cytometry, and 
conventional magnetic-activated cell sorting (MACS). However, it still has shortcomings 
such as system complexity, relatively high fabrication cost as well as vulnerability to 
bubbles, which may hinder the device operation and damage the targeted cells. 
Based on the review of the currently available techniques for cell detection, a brief 
conclusion could be drawn here that there are limitations in terms of volumetric flow rate 
(i.e. volumetric throughput), system complexity, operation difficulty, fabrication cost, as 
well as robustness. Our ultimate goal is to develop a system that not only mitigates the 
above-mentioned shortcomings but also allows concurrent detection of both cells as well 
as molecules which cannot be effectively performed by the aforementioned methods. 
Therefore, the next section (1.3) will present a review of the state of the art on technologies 
that only perform biomolecular screening.  
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1.3 Current Systems for Biomolecular Detection 
As mentioned before, detecting molecular biomarkers is also important in disease 
diagnosis, prognosis and therapy. We will therefore discuss biomolecular screening assays 
in this section.  
There are numerous biomolecule screening approaches, which can be classified into three 
categories including methods that use labels (e.g. enzyme-linked immuno-sorbent assays 
(ELISAs)), label-free methods (e.g., surface plasma resonance (SPR), quartz crystal 
microbalance (QCM)), as well as MEMS-based techniques such as microcantilever 
deflection, grating diffraction-based biosensors and magnetic nanosensors [42-47]. The 
methods in the latter category may overlap with label-based or label-free methods to a 
certain degree, in that they may or may not use labels. We however chose to place them in 
a separate category since they are different from mainstream commercial label-based and 
label-free platforms, owe their existence to advances in micro and nanotechnology and are 
still in the research phase. Since the primary goal of this thesis is to realize concurrent 
detection of cellular and molecular targets rather than pushing the limits of one particular 
biosensor, we mainly focused on commercially available systems and summarize them 
below. 
1.3.1 Label-based Methods 
Label-based methods depend on the use of molecular labels covalently attached to the 
biomolecules of interest to facilitate detection of the labeled biomolecules. Enzyme-linked 
immunosorbent assays (ELISAs), in various forms are the gold standard of biomolecular 
detection today. They are plate-based assays designed for detecting and quantifying 
substances such as peptides, proteins, antibodies and hormones. Typically, an ELISA assay 
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is designed for single analyte measurement. Among various forms of ELISAs, sandwich 
ELISAs is used to detect sample antigens. In a sandwich ELISA (Figure 1.4), a plate is first 
coated with a capture antibody; sample is then added so that antigens present can binds to 
the capture antibody. Following that, detection antibody is added, and binds to the antigen. 
Next, enzyme-linked secondary antibody is added which binds to the detection antibody. 
Finally, a substrate is added, which is converted by the enzyme to a detectable form [48]. 
Sandwich ELISAs allow biomolecules to be detected at low concentrations (pico-molar). 
A disadvantage is that the readout of ELISAs involves multiple antibodies which adds 
complexity to the assay. Also like any platform that uses a fluorescent or colorimetric signal 
for detection, inherent autofluorescence or optical absorption of the matrix or reagents can 
lead to errors [47].  
 
Figure 1.4. Schematic of a basic ELISA assay [48]. 
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Besides the single-analyte measurement techniques, there has been developments in 
multiple biomolecular analyte detection. Multiplex assays invented by Luminex 
Technology use bead-based flow cytometry to detect and sort multiple analytes 
simultaneously. This technique performs a sandwich immunoassay using magnetic beads 
that have internal dyes to achieve capture, separation and quantification of multiple classes 
of biomolecules at the same time (Figure 1.5). However, Luminex multiplex technology 
still has disadvantages which are common to multiplex assays such as possible cross-
reactivity between antibodies. Sensitivity may also be compromised when increasing 
number of beads has to be used for multi-target detection [49]. Moreover, Luminex 
technology is not cost-effective compared to normal bead-based assays which does not 
need specialized color-coated beads.   
 
Figure 1.5. Schematic graph of the multiplex Luminex assay. Note: in step 1-4, only one bead is shown to capture one type of analyte; in step 5, multiple color-coated beads were screened and profiled according to their color codes. 
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1.3.2 Label-free Methods  
As opposed to label-based techniques, label-free methods detect targets without requiring 
any type of radio, enzymatic- or fluorescent-labelling to report the binding event. The 
general advantages of label-free techniques are real-time monitoring of binding events, 
elimination of labelling procedures which cuts down on cost, as well as direct information 
from the target (as opposed to information from a tag that is attached to the target) [50]. A 
disadvantage of these systems is that non-specific binding effects at the sensor surface must 
be carefully controlled [51, 52]. Another problem is to ensure that the transfer of the analyte 
to the ligand at the sensor surface is not limited, otherwise the analyte concentration near 
the surface may be different from the bulk concentration (referred to as mass transport 
limitation) [53]. There are various types of label-free methods, among which surface 
plasmon resonance and quartz crystal microbalance are typical techniques for biomolecule 
screening. 
Surface plasmon resonance (SPR): SPR is the resonant oscillation of electrons at the 
interface between a negative and positive permittivity material stimulated by incident light 
[54]. As shown in Figure 1.6, the metal chip (silver or gold) is prepared with a dextran 
surface which can conjugate protein to the metal surface. At the bottom a single wavelength 
laser beam enters a prism which results in lights with multiple angles striking the metal 
surface. The light with specific angle will be absorbed by the metal and its energy will be 
turned to a plasmon wave onto the outer surface of the metal. At this angle, no light is 
reflected and thus appears with very little intensity on the detector. Since the plasmon wave 
propagates on the outer side of the metal, any interaction with the conjugated protein will 
change the resonance angle [55]. Generally, the resonance condition is achieved when the 
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frequency of incident photons matches the natural frequency of surface electrons 
oscillating against the restoring force of positive nuclei, and the natural frequency is a 
function of the amount of targets attached to the device surface. One fundamental problem 
is that SPR cannot perform high-throughput detection. The typical sample volume is 
around 100 µL, which is a major limiting factor when large volume (e.g. 7.5 mL) analysis 
is required. Also, SPR assays are usually performed in clear buffer solutions and are 
difficult to operate in complex media such as blood.  
 
Figure 1.6. Scheme of surface plasmon resonance [55]. 
Quartz crystal microbalance (QCM): As opposed to the SPR which measures optical 
signals, a QCM measures mass added onto the sensing surface. To be more specific, “mass 
per unit area” is measured by monitoring the change in the frequency of a quartz 
crystal resonator as a function of mass absorption onto crystal surface (Figure 1.7) [56]. 
The resonance is perturbed by the addition or removal of a small mass due to molecular 
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binding at the surface of the acoustic resonator. In addition to those common limitations 
(e.g. non-specificity) with label-free techniques, a QCM must be operated under well-
controlled conditions such as quartz plate thickness, density of quartz and temperature [57]. 
For example, the temperature of the setup must be very precisely controlled as this will 
significantly influence the resonance frequency of the quartz crystal [58]. 
 
Figure 1.7. Schematic of quartz crystal microbalance. The QCM measures mass changes on the sensor chip. A sensor, the key of QCM, oscillates at a specific frequency when voltage is applied. The frequency of the oscillation is dependent on the mass on the sensor due to adsorption or binding of molecules. 
Cantilever sensors: Researchers have explored other state-of-the-art sensing modalities 
enabled by the technological advances in micro and nanofabrication particularly over the 
last decade.  The Manalis group at MIT reported label-free protein detection using a 
microfabricated cantilever-based sensor (Figure 1.8). The cantilever surface was 
functionalized with DNA aptamers to act as receptor molecules [59]. Upon binding of 
target analytes, a change in surface stress causes the cantilever to bend. The dual-beam 
cantilever configuration constituted a sensor/reference pair and enables direct detection of 
the differential bending between the two cantilevers using the diffraction of a laser beam. 
Cantilever sensor realizes label-free detection, but requires precise control of laser power, 
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and other experimental conditions. Also, the lack of physical understanding of the 
relationship between the molecular binding and the resulting surface stress makes 
quantification difficult.  
 
Figure 1.8. Schematic of the cantilever-based sensor. Aptamers were immobilized onto the sensor surface as molecule receptors to bind ligands of interest. The differential bending is measured directly using interferometry. 
The goal of this thesis study is to develop a novel platform that can detect both cells and 
molecules. Hence, an appropriate molecular detection modality that can be integrated into 
the same package that performs cell detection is needed. Such a modality should either be 
selected from the available ones or be invented from scratch. We therefore summarize 
below the molecular detection platforms in this context. 
All of the biomolecular sensors and platforms that have been discussed in sections 1.3.1 
to 1.32 have their advantages as well as limitations. Some systems (e.g. ELISA) show great 
performance in limit of detection (LOD) but are difficult to realize outside their dedicated 
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hardware (i.e. 96-well plates and plate readers) and standardized amplification reagents 
which also make it challenging to adapt these systems to the analysis of large volumes of 
samples (i.e. limited throughput). Some systems (e.g. SPR, QCM) have the capability of 
label-free screening and hence do not require as many or any reagents needed by ELISA, 
but only at the expense of lower resolution, which is the main reason why label-based 
techniques still constitute the gold standard in molecular detection. Also these platforms 
are designed mostly to analyze small volumes of samples and hence are not directly 
amenable for high volumetric throughput detection. We seek to develop a system that can 
target rare entities, hence being able to analyze relatively large, multi-milliliters of sample 
volumes. Hence, being able to perform high-volumetric throughput detection is critical to 
a system that aims to process 7.5 mL or more sample volume (this is the volume of a typical 
blood sample collected in a hospital lab). The Luminex multiplex assay does show good 
performance in all those areas. The Luminex technology can be configured to either cell 
sorting or protein screening. It however cannot quantitatively detect the two targets at the 
same time. Further, the specialized beads (that are inherently fluorescent) used by the 
Luminex system limit its versatility and adds to its cost. 
1.4 Concurrent Detection of Cellular and Molecular Targets 
As mentioned before, most biosensing systems are mainly developed to detect only one 
type of a target: either molecules or cells but not both. It is possible to use these systems to 
detect both types of targets but it requires a significant amount of modification and 
optimization of experimental conditions and procedures to switch from one mode to the 
other. This thesis presents a system that can simultaneously capture and analyze both cells 
and protein biomolecules present in a sample fluid. The system has excellent capability to 
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process large sample volumes in a short time. Also, large amount of sensing substrates as 
well as multiple ligands can be integrated to further improve detection yield. Lastly, 
captured cells can be retrieved for downstream analysis while advanced protein screening 
tool can be integrated for high-performance detection. In this new system magnetic 
particles functionalized with antibodies against target biomolecules as well as surface 
antigens on target cells are used to capture the two targets (Figure 1.9). Bead-bound cells 
and bead-bound molecules are then pumped into a fluidic device where a permanent 
magnet is placed beneath the device to capture magnetic particles and any target entities 
bound to them. 
 
Figure 1.9. Scheme of dual-target detection. 
Two generations of the systems have been developed. A single-layer fluidic device (first 
generation system) was first developed, in which cellular and molecular targets were 
captured and analyzed together on its glass surface. As we will also describe later, due to 
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the inability of the system to 1) separate one type of analyte from the other (even though it 
can detect them) and 2) process large number of beads, first generation system had limited 
efficiency in targeting more than one analyte.  
To achieve higher detection efficiency as well as better compatibility with other 
downstream applications and standard laboratory equipment, the second-generation device 
was developed. This upgraded system is a combination of immunomagnetic separation and 
size-based filtration. It consists of a dual-layer microfluidic device wherein a micro-
aperture chip was inserted as the interface between the top and the bottom chambers. By 
virtue of the micro-aperture chip, beads attached with target molecules, owing to smaller 
size (1~2 um), are drawn down to the bottom chamber through the holes, while the target 
cells bound with beads are retained on the chip surface. There are multiple advantages of 
micro-aperture system over the single-layer system. Lager number of beads can be used to 
realize multiplex assay as well as to increase cell detection yield. Moreover, even though 
it is not within the scope of this thesis study, this system can be adapted with commercial 
assays such as Luminex by directly replacing magnetic beads with color-coated magnetic 
beads. Post-detection analysis could be another potential benefit of using the concurrent 
detection system in cell-relevant studies. For example, subsequent analysis of recovered 
captured rare cells can further lead to the discovery of new mutations and expand our 
understanding of cancer biology via DNA/RNA sequencing [19, 31, 32]. 
1.5 Thesis Organization 
The first-generation device, a single layer fluidic system, is presented in Chapter 2. The 
forces within the system were modeled numerically for simulating the particle trajectories 
to understand favorable operating conditions. The system was characterized in terms of its 
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response to free protein concentration, as well as its yield in detecting cells spiked in 
complex mixtures. To demonstrate the system’s potential in clinical applications, we 
detected free FR and KB cells spiked into healthy human blood, as well as endogenous FR 
and FR+ cells present in the ascites obtained from an ovarian cancer patient.  
In Chapter 3, the development of the second-generation device, which employs a micro-
aperture chip that was embedded to sort cellular targets, is presented. Even though the 
ultimate goal of this thesis is to develop a system that can detect both cells and molecules, 
this chapter focuses on the cell-detection aspect of the device. System design, device 
fabrication and assembly, modeling (i.e. cell capture yield, working mode), as well as 
characterization of the system with respect to detection and isolation of CTCs are discussed 
successively. Finally, on-chip detection of CTC numbers from actual cancer patient blood 
are demonstrated. 
The improved version of the device presented in Chapter 3, i.e. the dual cellular and 
molecular detection system is the topic of Chapter 4. Separation and dual detection of 
prostate cancer cell and molecular molecule biomarkers is discussed.  This chapter begins 
with system and device assembly and numerical modeling, which is followed by 
characterization of the system in separation and dual detection of the two targets spiked 
culture medium and healthy human blood. Detection and isolation of the model prostate 
cancer tumor cells (LNCaP cells) and prostate cancer molecular markers (PSMA) from the 
same sample fluid is presented in this chapter. 
In Chapter 5, post-detection applications such as cultivation of captured cells (e.g. CTCs) 
for future analysis is present first. Potential for future work, which will be focused on single 
cell manipulation (e.g. selectively picking up single cells with a pipette-syringe 
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manipulator), dual detection of cells and molecules from cancer patient blood, as well as 




CHAPTER 2. FIRST-GENERATION SYSTEM 
2.1 Introduction 
This chapter presents a basic device that can capture and detect cells and molecules 
of interest in a complex fluidic mixture. In this first-generation system, magnetic 
particles functionalized with antibodies against target biomolecules as well as 
surface antigens on target cells are used. However, the peripheral fluidic, 
sample/waste collector, permanent magnet, and other experimental components are 
intentionally simple to demonstrate the proof-of-concept. The bead-bound targets 
(both proteins and cells) are captured magnetically on the surface of a glass slide 
(which constitutes the “chip” of the first-generation system) under high volumetric 
flow rates (2-3 mL/min). High volumetric flow rate is necessary for processing large 
sample (~7.5 mL) in order to capture rare cells with a concentration of less than 10 
per mL. The method is versatile enough that beads conjugated with a variety of 
antibodies can be combined to target various molecular targets and cell surface 
antigens. The method becomes especially simple for applications wherein the free 
biomolecular target is also overexpressed on the target cell surface, e.g. free prostate 
specific membrane antigen (PSMA) and PSMA+ tumor cells, and free epidermal 
growth factor (EGFR) and EGFR+ tumor cells. Chapter 2 mainly focuses on 
detecting free folate receptor (FR) and FR+ tumor cells. Folate (vitamin 9 or pteroyl-
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L-glutamic acid) is a B vitamin, which is required by all living cells 
for nucleotide biosynthesis and for the proper metabolic maintenance of 1-
carbon pathways [60]. FR, also known as folate-binding protein, captures folate and 
mediates delivery of folate to the interior of cells. Both normal epithelial cells and 
carcinomas express FR to some extent, however epithelial-derived tumor (e.g. ovarian, 
breast, renal, lung, colorectal, and brain) cells overexpress FR [61, 62]. Thus, a number of 
studies showed that FR is a biomarker for several epithelial malignancies [24-26]. It has 
also been shown that ovarian cancer patients have elevated serum levels of FR alpha, which 
is over-expressed on the surfaces of malignant cells and eventually shed into the blood as 
free FR [27]. 
The detection strategy is illustrated in Figure 2.1. Superparamagnetic particles are 
first conjugated with polyclonal antibodies against FR (anti-FR). These anti-FR 
beads are then introduced into a sample fluid containing FR and FR+ cells for 
incubation (Figure 2.1 (a)). The incubated sample mixture then flows through a 
fluidic chamber made of a PDMS channel and two glass slides (Figure 2.1 (b)). 
During the flow, target cells and molecules are attracted to the surface of the bottom 
glass (the chip) slide in a magnetic field generated by a magnet placed beneath the 
chamber, while other entities in the sample fluid are washed away under a high 
volumetric flow (~3 mL/min). Finally, captured targets are quantitated using 






Figure 2.1. Schematic showing the operation principles. (a) FR molecules and FR+ KB cells bound to anti-FR beads; (b) Microfluidic chamber designed for immunomagnetic detection of KB cells and free FR: KB cells and FR are simultaneously captured by the magnetic field as the sample fluid flows through the chamber; (c) Bright-field (c.1) and fluorescent (c.2) images obtained from the same detection surface. White arrows point to the captured cells. 
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2.2 System Overview 
2.2.1 System Setup 
The system is built based on the schematic shown in Figure 2.1 (b). To configure 
the experimental setup, a fluidic chamber was first constructed by placing a 
patterned PDMS layer (thickness of 1.5 mm) between glass slides (thickness of 1mm) 
as a spacer. The inlet and outlet of the fluidic chamber were made through an 
opening on the glass slide where tubing was connected. A laser cutter was used to 
define the dimension of the fluidic channel by forming a 30 mm by 3.8 mm opening 
in the PDMS layer. The fluidic chamber was mounted on a hollow acrylic stand 
(shown in Figure 2.1 (b)), in which a neodymium permanent magnet was inserted to 
provide a magnetic field from below. The inlet of the chamber was connected to the 
fluid source while the outlet was connected to a peristaltic pump (New Era Pump 
Systems, NE-9000) and drained into a waste container or a collection tube (Figure 
2.2).  
 
Figure 2.2. Experimental setup of the entire system. 
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2.2.2 Device Assembly 
The device consists of seven basic components: acrylic cover, acrylic stand, top 
glass fluid cover, bottom glass fluid cover, fluid channel (PDMS layer) and magnet. 
The assembly scheme is shown in Figure 2.3. 
 
Figure 2.3. Exploded view drawing of the first-generation system. 
Fluid channel: The fluid channel is defined by a PDMS (polydimethylsiloxane) 
frame sandwiched between the two glass slides. PDMS is optically clear, chemically 
inert, non-toxic, and non-flammable. Thus it is one of the most widely used materials 
in microfluidics and bio-MEMS [63]. 
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A laser cutter (Universal Laser Systems, VLS 3.60) was used to define a 
rectangular channel (30 mm by 3.8 mm) in the PDMS layer. 
Fluid cover: Top and bottom fluid covers are made of laboratory glass slides. The 
thickness of each glass slide is 1 mm. The inlet and outlet of the chamber were 
inserted on the top cover slide by drilling two holes using a mechanical drill with a 
diamond drill bit. Silicone elbow tubing was then inserted through the holes and 
sealed in place using superglue. 
Acrylic stand and cover: The fluidic chamber assembly is mounted on an acrylic 
stand to prevent the fluidic chamber from leaking as well as to allow the placing of 
a magnet at the bottom of the chamber. Both the cover and stand are made of acrylic 
(Poly (methyl methacrylate)). Acrylic is a transparent thermoplastic often used as a 
lightweight or shatter-resistant alternative to soda-lime glass, especially when 
extreme strength is not needed. Another reason we chose acrylic glass is because it 
can be patterned easily using a laser cutter. 
The top fixture has a large rectangular window in the central area, which is used 
for observing the detected targets. The inlet and outlet of the top fluid chamber also 
go through this window. The bottom fixture has a square window for inserting a 
magnet. The device assembly was fixed and tightened on the acrylic stand using four 
pairs of bolts and nuts. 
Permanent magnet: We used a neodymium magnet (K&J Magnetics, grade N52) 
to provide magnetic force to draw magnetized entities to the glass chip surface. 
Neodymium magnet is one of the most widely used type of rare-earth magnets and 
is made from an alloy of neodymium, iron and boron to form the Nd2Fe14B 
27 
 
tetragonal crystalline structure. The dimension of the block magnet we used is: 
3/8"×3/8"×3/8", which is inserted into the opening of the bottom fixture to be 
positioned beneath the fluidic chamber. The magnetic flux density of the magnet is 
0.6451 Tesla on its surface. 
Our characterization of the system involved detecting free FR molecules as well 
as FR+ cells in the same sample fluid. We describe below the experimental 
conditions and protocols we have used for this characterization and testing process. 
2.3 Methods and Materials  
2.3.1 Preparation of FR antibody-coupled Magnetic Beads.  
To prepare the anti-FR beads, streptavidin-coated 1 µm magnetic beads (20 µL, 10 
mg/mL, Sigma Aldrich) were incubated with biotinylated polyclonal antibodies against FR 
(10 µL, 0.2 mg/mL, R&D Systems) in a phosphate buffered saline (PBS) solution at room 
temperature for 1 hour. After incubation, the beads were washed 3 times with PBS using a 
magnetic stand to remove unbound antibodies. 
2.3.2 Preparation of KB Cells and FR.  
FR+ KB cells, obtained from American Type Culture Collection, were cultured in folic 
acid depleted RPMI 1640 medium (Gibco, USA) with 10% fetal bovine serum (FBS). 
Before the spiking process, KB cells were harvested using Trypsin-EDTA (Invitrogen) and 
re-suspended in culture medium. Cell concentration was measured by taking 5 samples 
(each with a volume of 3 µL) and manually counting the cell number to obtain an average. 




Recombinant human folate receptor (FR) was purchased from R&D systems and stored 
at -20℃ with a concentration of 100 μg/mL in PBS. FR was diluted and added into medium 
or blood to desired concentrations for characterization and detection experiments. 
2.3.3 Blood Samples for KB and FR Spiking Experiments.  
Blood was collected from healthy volunteers under an approved IRB protocol. De-
identified blood samples were drawn and collected in BD vacutainer tubes with additives 
of sodium polyanethole sulfonate (SPS). Blood samples were kept at 4 C immediately 
after collection until the spiking process. Blood samples were used within 12 hours after 
being collected (usually within 4 hours) to ensure the viability of blood cells.  
2.3.4 Ascites Sample for Dual-target Detection.  
Ascites from a recurrent ovarian cancer patient with stage IIIC high grade serous primary 
peritoneal carcinomatosis was collected at the Indiana University Hospital and kept at -20 
C until experimentation. Prior to processing the ascites fluid was thawed and filtered (pore 
size: 100 µm) to remove large impurities in the fluid.  
2.3.5 Fluorescent Staining for Free FR and FR+ Cell Quantification.  
Earlier studies have shown that fluorescein isothiocyanate-conjugated folate, i.e. folate-
FITC, is effective in imaging FR+ malignant tumors with very low background in FR- 
malignant or benign lesions [64]. In this study, 10 μM of folate-FITC was used to stain 
both free FR molecules and FR+ cells captured by the anti-FR beads. Free FR molecules 
were sandwiched between the folate-FITC and the anti-FR on the beads. While detecting 
cells, folate-FITC not only made it easier to identify whole cells on the glass surface but 
also served as an independent check for FR positivity (in addition to the antibody mediated 
bead binding which can be observed in bright field). For characterization experiments 
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performed in media, folate-FITC was incubated with captured targets under static 
conditions at room temperature for 1 hour. For analysis of bodily fluids, 34 nM of CD45 
monoclonal antibodies conjugated with phycoerythrin (anti-CD45-PE, Abcam, USA), and 
0.18 μ M of 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, USA) were also 
introduced in addition to folate-FITC to recognize white blood cells and to identify 
nucleated cells.  
For experiments that involved blood, red blood cell (RBC) lysis buffer (G-Biosciences, 
USA) was introduced into the chamber after the cell capturing process, and incubated for 
5 minutes to remove residual RBCs. Cells captured on the glass surface were then fixed 
using 4% paraformaldehyde (PFA, Santa Cruz Biotechnology, USA) in PBS. Folate-FITC, 
anti-CD45-PE and DAPI were subsequently introduced into the fluid chamber and 
incubated under static conditions at room temperature for 1 hour. After incubation, the 
fluidic chamber was washed with PBS at a flow rate of 4 mL/min for 30 seconds, and was 
subjected to fluorescence microscopy for enumeration of the cancer cells as well as 
quantification of FR concentration. 
2.4 Results and Discussion  
2.4.1 Modeling and Simulation 
To assess the system functionality in capturing magnetic particles we generated a 
computer-based numerical simulation using COMSOL Multiphysics 4.3a modeling 
software. COMSOL Multiphysics is a finite element analysis, solver and simulation 




We first modelled the magnetic and fluidic fields inside the fluidic chamber and 
defined the primary forces acting on an entity inside the chamber. Then a particle 
trajectory module (PTM) was applied to obtain the trajectories of 300 beads and 30 
cell-beads complexes. Here 30 is a number close to the number of CTC present in 
patient blood, while 300 was the maximum number of particles that our computer 
was able to handle within its computational capacity. This number however was 
sufficient to obtain an intuition on how the particles behave under the influence of 
flow and magnetic force. 
Magnetic field modeling. We first simulated the magnetic field generated by the 
permanent magnet placed underneath the fluidic chamber. COMSOL provides a 
module, “Magnetic Fields, No Currents”, to simulate the magnetic field associated 
with a permanent magnet. This module requires users to input three groups of 
parameters: 1. magnetic properties including vacuum permeability (ߤ௢ ), relative 
permeability (ߤ௥), remanent flux density (ܤ௥) and magnet dimensions; 2. boundary 
conditions and initial values; 3. a constitutive relationship (ܤሬԦ = ߤ௢ߤ௥ܪሬሬԦ + ܤ௥ሬሬሬሬԦ). Then 
the software solves the partial differential equations using finite element methods to 
obtain the numerical magnetic field information such as flux density with 
corresponding spatial coordinates. 
Figure 2.4 shows the distribution of the flux density. Simulated results indicate 
that in the vertical direction the magnitude of the magnetic flux density decreases as 
the distance from the magnet surface increases; while in horizontal direction the 
maximum magnitude occurs at both edges of the magnet. Once we have the 
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magnetic flux density, we can calculate the magnetic force acting on magnetized 
particles passing through the chamber. 
 
Figure 2.4. (a) The colormap of magnetic flux density magnitude. (b) The distribution of flux density magnitudes. The lateral (x-coordinate) range it starts from the left edge of the magnet to end at the right edge. Solid lines with different colors represent flux density magnitudes (|B|) at different distances from the magnet surface. 
Fluid field modeling. The fluid field was simulated using another COMSOL 
module. This begins with calculating the Reynolds number to determine the flow 
type. According to the fluidic channel dimensions (length, 25.4 mm × width, 3.8 
mm × height, 1.5 mm) and the flow properties, the Reynolds number was calculated 





that we input fluid-related properties including: inlet flow rate, dynamic viscosity, 
fluid density as well as channel dimensions. Then the software solves the partial 
differential equations using finite element methods to obtain the numerical fluid 
field information such as velocity spatial distributions. This information can be used 
to solve for the fluid force acting on all particles passing through the chamber. Figure 
2.5 indicates the simulated results of the fluid field inside the single-layer fluid 
chamber. Figure 2.5 (a) shows a color map representing the velocity magnitude at a 
flow rate of 3 mL/min, and Figure 2.5 (b) is a magnified region of the fluid field 
where black arrows denote the direction and magnitude of fluid velocity with the 
corresponding spatial coordinates. This means that flow velocity is maximum in the 
center of the channel while approaching zero near the walls. 
      




Multi-domain modelling. The forces acting on a particle (either a single bead or a 
cell-bead complex) in the chamber include the magnetic force, the drag force induced by 
the flow, gravity, and the buoyant force. To simplify the simulation, we assumed that the 
internal magnetization between the particles, the influence of the particles on fluidic field, 
and the coupling between fluidic and magnetic fields were negligible. We further assumed 
that the magnitude of the magnetic force acting on each cell-bead complex is directly 
proportional to the number of the beads bound to that particular cell, since this force acts 
directly on the beads not on the cells themselves. The magnetic force F୫ሬሬሬሬሬറ, which is one of 
the dominant forces in the system, can be estimated by [65, 66]: 
ܨ௠ሬሬሬሬሬറ = ܰ ௏ఞଶఓబ ∇൫ܤሬറ ∙ ܤሬറ൯                                                                                   (2.1) 
where V is the volume of the particle (2.4×10ିଵ  mଷ for a KB cell and 5.2×10ିଵଽmଷ 
for a magnetic bead); χ =2.7 the effective volumetric magnetic susceptibility; μ଴  the 
vacuum permeability; and BሬԦ the magnetic flux density, which is shown in Figure 2.4 (a). N 
is the number of beads attached to a cell and is simply equal to 1 for the case of a free bead.  
The resulting magnetic force applied on a bead at the detection surface (~1.1 mm from 
the magnet top surface) in the chamber is shown in Figure 2.6. Blue solid line represents 
lateral magnetic force whereas green dashed line represents the vertical magnetic force. It 
can be inferred from the simulation that the magnetic force tends to pull down (y-
direction force) the magnetized particles (bead and cell-bead complex) passing 





Figure 2.6. The corresponding magnetic force induced on a single bead on the detection surface. The blue solid line shows the force in X (lateral) direction while the green dashed line indicates the force in Y (vertical) direction.  
In order to evaluate the force exerted on a cell that is attached to a plurality of beads, we 
first determined the number of beads binding to a single cell. We performed an experiment 
where, 500 KB cells were incubated with 20 µL of anti-FR beads for 1 hour. Following 
that, 50 bead-bound cells were randomly selected. The number of beads bound with each 
cell was counted using bright field microscopy and plotted in Figure 2.7. The average 




Figure 2.7. Histogram of number of beads per KB cell. 
In our simulations we only considered the lower end of this range where N=10 beads/cell 
to account for a conservative scenario: if a cell with the minimum number of beads can be 
captured, then cells with more beads should also be captured under the same conditions. 
The more complex scenario of different number of beads binding to a single cell will be 
discussed and analyzed in Chapter 3 where efforts will be focused on elimination of white 
blood cells (WBCs) that are non-specifically tagged with magnetic beads. 
To perform the simulation, several forces (e.g. fluid drag force, magnetic force, gravity, 
etc.) acting on particles are combined into the Newton second law. The fluid drag force Fୢሬሬሬሬറ, 
the other dominant force, acting on a cell-beads complex is given by [65, 66]: 
ܨௗሬሬሬሬറ = 6ߨߟݎ௣൫ ሬܷറ − ௣ܸሬሬሬറ൯                                                                    (2.2)                                                                                 
where η is the fluid dynamic viscosity (10ିଷkg mିଵ sିଵ); r୮ the radius of particle (0.5 µm 




The buoyant force Fୠሬሬሬሬറ can be expressed by: 
Fୠሬሬሬሬറ = −ρgሬԦV                                                          (2.3) 
where ρ is the density of the fluid (1000 kg mିଷ ), gሬԦ is the gravitational acceleration, V is 
the volume of the particle (2.4×10ିଵହ mଷ for a cell-beads complex and 5.2×10ିଵଽmଷ for 
a single bead). 
F୥ሬሬሬሬԦ is the weight of the particle: 
F୥ሬሬሬሬറ = m୮gሬԦ .                                                          (2.4) 
The buoyant force can be expressed by: 
ܨ௕ሬሬሬሬറ = − ሬ݃Ԧߩܸ .                                                      (2.5)                                                                           
Newton’s second law yields: 
݉௣ ௗ௏೛ሬሬሬሬറௗ௧ = ܨ௠ሬሬሬሬറ + ܨௗሬሬሬሬറ + ܨ௚ሬሬሬറ + ܨ௕ሬሬሬሬറ                                                                              (2.6)                                   
where V୮ሬሬሬሬԦ is the velocity of the particle, and m୮ is the mass of the particle, which could 
be either a single free bead or a bead-cell complex. The average mass of a dry KB cell, 
which is approximately 30% of the original mass, was measured to be 760 pg using a 
cantilever-based resonator [67]. Hence the mass of a single ‘wet’ cell was taken as 2533 
pg, which is in agreement with a previous study [68]. The mass of a single magnetic bead 
with 1 µm diameter is around 1 pg. Thus the mass of a cell bound with N beads is 2533+N 
pg. 
Once the finite element simulation provided the velocity and displacement information 
for beads and cell-beads complexes inside the fluidic chamber, we calculated their 
trajectories and final locations on the chip surface. This relatively simple computational 
model only accounts for a particle’s trace until it reaches the chip surface (not what happens 
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thereafter e.g. bouncing off or sliding on the chip surface), yet it helps understand the 
interplay between the magnetic and fluidic forces and suggests optimal operational 
conditions including flow rate.  
Simulation-based analysis. Flow rate is critical to cell detection yield, since it 
determines how easily the magnetically-tagged cells escape from a given magnetic field. 
We primarily studied the effect of flow rate on the trajectory of cells within the fluidic 
chamber when they are bound with 10 magnetic beads. We simulated a scenario where 300 
cells, each bound with 10 beads, flow though the fluidic chamber under the influence of a 
high volumetric flow rate that varies from 1 to 6 mL/min.  
Figure 2.8 (a) shows the simulation of the final distribution of 300 superparamagnetic 
beads on the detection surface at a flow rate of 3 mL/min. Also shown are micrographs 
taken from different locations on the chip surface after an experiment performed under the 
same conditions (only the number of beads used in the simulation was deliberately kept 
small to reduce computation time). The two results are in good agreement in terms of 
describing beads’ distribution. Figure 2.8 (b) shows the simulation results where 30 KB 
cell-bead complexes (blue dots) along with 300 free beads (red dots) were introduced into 
the chamber under various flow rates. The capture rate of bead-bound KB cells was 
calculated accordingly by dividing the number of cells arriving glass surface to the total 
number of cells introduced and was plotted against the flow rate in Figure 2.8 (c). This 
figure shows that when flow rate is as high as 4 mL/min, the system starts to lose cells. On 
the other hand, when the flow rate is too low (< 2mL/min), even though theoretically the 
cell recovery rate should be high, we observed that the beads tend to accumulate in small 
areas, resulting in practical difficulties in imaging and discriminating cells. Hence it was 
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determined that the optimized balance between throughput and cell recovery rate can be 
achieved at a flow rate of 3 mL/min. 
 
 







Figure 2.8. Continued 
After system design and fabrication was completed, the system was characterized 
experimentally by spiking known number of targets into cell culture media and observing 
the amount of targets detected. We first describe the characterization of the system for 
detection of molecular markers only. We then follow with the characterization for 
concurrent detection of both cellular and molecular targets. 
2.4.2 System Characterization for Molecular Detection 
We first characterized the system for detection of molecular markers only by detecting 
known concentrations of FR (molecular mass: 25.4 kDa) added into 1 mL of culture media. 
The anti-FR beads were incubated with the samples at room temperature for 1 hour to 
capture the free FR. The mixture was then flowed through the detection chamber at a flow 
rate of 3 mL/min, and the magnetic beads were pulled down and held on the detection 
surface by the magnetic field. Afterwards, the chamber was rinsed with PBS to wash away 
those unbound FR molecules and impurities. The accumulated beads were subsequently 
incubated with folate-FITC for 1 hour at room temperature to stain the FR captured on the 
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beads for fluorescent analysis. Figure 2.9 shows the fluorescent and corresponding bright 
field micrographs of the beads captured on the detection surface with 3 different FR 
concentrations, 100 nM, 1 nM and 0 nM. The intensity of the fluorescent signal emitted 
from the beads increases with the FR concentration. The bright-field image provides 
information of the existence and distribution of beads on chamber surface. 
 







Algorithm for calculating effective fluorescence. To study the relationship between the 
input (FR concentration) and the output (fluorescence) signals, we calculated the total 
fluorescence intensity in an observation window and subtracted the background intensity 
observed in a bead-free area in the same window. This fluorescence intensity was then 
normalized by the intensity of the reversed bright field image, which represents the number 
of the beads on the detection surface. The resulting signal, called the “B-ratio” (which 
stands for “brightness ratio”), is a measure of the fluorescence signal per bead and can be 
used to establish a detection curve.  
Figure 2.10 shows the flow chart of B-ratio calculation. Fluorescent and bright field 
images are taken from the same area. Fluorescent image is first split into three channels 
with respect to red, green and blue colors, and then red and blue channels are filtered out. 
The green image is converted into grayscale image; a median filter (size: 110×110) is used 
to extract the background of the image. The total fluorescent intensity is then calculated 
after subtracting the background. For a bright field image, it is first converted to grayscale 
image and the intensity is reversed. Then the total bright-field intensity is calculated. The 





Figure 2.10. Flow chart of B-ratio calculation. 
To examine whether the B-ratio is significantly dependent on bead densities (i.e. number 
of beads over a given surface area), two pairs of images with different number of beads 
were selected for the test. As shown in Figure 2.11, under the same FR concentration (100 
nM), two pairs of images were collected from different regions of the detection surface. 
The total fluorescent intensity calculated from Figure 2.11 (a.2) is 51.3% higher than that 
calculated from Figure 2.11 (b.2). However, the difference in B-ratio in between the 2 pairs 
of images is only 1.4%. Therefore, we conclude that B-ratio is a better output metric than 




Figure 2.11. Two pairs of bright field and fluorescent images obtained from different locations on the detection surface. There is an obvious difference in bead distribution density between (a) and (b). The B-ratios of the two pairs, however, are very close to each other, which indicates the robustness of this algorithm in computing fluorescent intensity per bead.  
B-ratio vs. molecule concentration. We measured the B-ratio obtained from 8 various FR 
concentrations in medium from 0 to 200 nM and plotted them in Figure 2.12. For each 
measurement 3 images were acquired at different locations of the glass surface. Performing 
a least squares Langmuir isotherm fit to the experimental data revealed:  
B୰ = ଴.ଵଶଽଽଵାభ.బఱఱ ి౜⁄ + 0.08504                                                                                              (2.7)                                     
where B୰ is the B-ratio and C୤ is the FR concentration; 0.08504 is the bias which could 
result from the non-specific binding between folate-FITC and anti-FR beads and/or the 
intrinsic fluorescent background of the magnetic beads. The dissociation constant Kd 
between anti-FR and FR was found to be around 1.055 nM, which is in agreement with 
previous reports [69, 70]. 
From Figure 2.12 the dynamic range of this system for detecting FR is from 10 pM to 





detect concentrations as low as 10 pM (with a 3-standard deviation difference from the 
background). Although we were also able to measure lower signals at 1 pM, such signals 
did not differ significantly from that of 10 pM. Clinical research shows that for ovarian 
cancer patients the level of circulating FR can vary from 70 pM to 2 nM [46, 62, 71], and 
thus our system is capable of detecting FR in cancer patient blood, which was further 
validated by detecting FR spiked into human blood and comparing the result with that 
obtained using an established method (e.g. ELISA). 
 
Figure 2.12. Variation of fluorescence with FR concentrations from 1pM to 200 nM. Error bars represent standard deviations from 3 measurements. Green horizontal line represents experimental background (Br when FR=0). Gray curve is the Langmuir isotherm fit based on Equation (2.7). 
2.4.3 Characterization of the System by Detecting FR-positive Cells in the Presence of 
Free FR 
We next characterized the system for simultaneous detection of both cellular and 
molecular targets. Around 100 KB cells and FR molecules with concentrations between 1 
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pM and 100 nM were spiked in cell culture medium with a volume of 1 mL. The mixture 
was then incubated with 20 μL (40 μg) of anti-FR beads for 1 h at room temperature before 
flowing through the fluidic device for detection. Following that, the fluidic chamber was 
subjected to folate−FITC staining and fluorescent microscopy to quantify the two targets 
(cells and molecules) detected on the glass surface. To eliminate the influence of the 
fluorescence signal coming from the cells on free FR quantification, the images of cells 
were deliberately removed from both fluorescent and bright field images before calculating 
the B-ratio (Figure 2.13).  
 
Figure 2.13. Bright-field (a.1, b.1) and fluorescent (a.2, b.2) images obtained from the same detection surface. In images b.1 and b.2 cells were deliberately removed for B-ratio calculation. Image b.1 is a reverse bright field image in grayscale. White arrows point to the locations of the captured cells. 
The detection yields of the KB cells and the measured FR concentrations are plotted 
against the concentration of free FR spiked in medium in Figure 2.14. We observed a 
monotonic relationship between spiked and measured free FR concentrations. The free FR 
concentration was estimated by comparing the measured B-ratio to the Langmuir isotherm 
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fit described by Equation (2.7). Therefore, the systematic accuracy of the estimated 
concentration is limited by how well the fit represents the calibration data with respect to 
how much the data varies in a specific concentration region. For example, for 
concentrations between 10 and 100 pM, as well as above 10 nM, the slope of the fit is 
relatively small, and hence, errors in B-ratio could result in larger errors in the estimated 
concentration. The difference between the Langmuir fit and the actual data can also lead to 
overestimation of the concentrations at the lower end of the dynamic range. In Figure 2.14 
the cell detection yield remains above 90% when the FR concentrations were below 10 pM. 
However, the detection yield starts to decrease with increasing FR concentration above 10 
pM. We attribute this to a competition effect between the KB cells and the free FR 
molecules, whose quantity and mobility is higher than that of the cells. A high level of free 
FR therefore masks the beads’ binding sites and lowers the number of FR+ cells captured 
by the beads (on the other hand, the presence of cells does not significantly hamper the 
capturing of molecules). Therefore, the plot in Figure 2.14 serves as a calibration curve to 
estimate the original number of cells present in a sample fluid based on the number of cells 




Figure 2.14. The detection yield of KB cells and the measured FR concentration plotted against spiked FR concentration. Blue circles represent the detection yield and error bar is one standard deviation from 3 measurements; while green squares represent the measured FR concentration. 
Besides concurrent detection of the two targets and quantifying them using fluorescent 
labeling, we also verified that the fluorescent signal coming from a FR+ cell is primarily 
due to the FR on the cell itself by imaging a KB cell that is not exposed to any beads (Figure 
2.15).  
 
Figure 2.15. Fluorescent images of KB cells with and without free FR. The left image is KB cells with zero FR but beads; the central one is KB cells with 1 nM of free FR and beads; the right one is KB cells without FR or beads. 
We also performed a negative control experiment wherein we used the same procedures 
in KB cell detection to attempt capturing 4T1 cell line (Life Technologies) that is known 
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to be FR-negative [72]. Only 1.4% of 4T1 cells were found on the detection surface. This 
experiment result indicate that anti-FR does not significantly target surface markers other 
than FR.  
2.4.4 Concurrent Detection of Molecules and Cells Spiked into Blood Samples 
To study the potential of the system in clinical applications, FR and KB cells were spiked 
into blood samples collected from a healthy donor. 500 µL of unprocessed whole blood 
was first diluted with PBS solution to 2 mL. Around 100 KB cells were spiked into the 
diluted blood sample and meanwhile free FR were also added to make the final FR 
concentration 200 pM. The mixture was incubated with 20 µL (40 µg) anti-FR beads at 4 
C for 90 mins. Each sample was then passed through the fluidic chamber (under the 
influence of the magnetic field) at a flow rate of 3.0 mL/min, which was followed by 
washing with 3 mL of PBS solution. The sample was subjected to fluorescence microscopy. 
We identified KB cells based on a combination of factors including the size (10-30 µm), 
shape (close to circular) of the observed cells and their fluorescent emissions, wherein a 
Folate-FITC(+), anti-CD45-PE(-), and DAPI(+) cell was scored as a positive result. Figure 
2.16 shows the fluorescent images of 3 KB cells and a leukocyte, as well as FR-beads 




Figure 2.16. Fluorescent micrographs of cells detected from KB spiked blood. (a) KB cells stained by folate-FITC; (b) Leukocytes stained by antiCD45-PE; (c) Cell nuclei stained by DAPI; (d) A merged image of (a)-(c). 
The FR level of the blood was measured to be 244 pM, which is slightly higher than the 
FR concentration we spiked in (200 pM). This could be attributed to the intrinsic FR 
present in the healthy blood. The number of KB cells detected on the chip was counted to 
be 62. Based on the measured FR level and the KB detection yield in Figure 2.14, the 
estimated total number of KB cells present in blood was calculated to be 98, which is in 
agreement with the number we spiked in (100). The set of experiments performed thus far 
50 
 
demonstrated the system’s capability to simultaneously detect rare cells and protein 
biomarkers from human blood. We next investigated the system’s potential to detect target 
entities in bodily fluids other than blood. 
2.4.5 Concurrent Detection of Free FR and FR+ Tumor Cells in Ascitic Fluid 
The system was finally challenged to detect FR and FR+ cells present in bodily fluids 
obtained from a cancer patient. For this purpose, ascites was obtained from a patient with 
stage IIIC ovarian cancer (high grade serous primary peritoneal carcinomatosis). Ascites is 
the accumulation of fluid in the abdominal cavity that occurs in a number of clinical 
conditions. In the case of ovarian cancer, the “ascitic fluid” or simply “ascites” normally 
contains protein biomarkers as well as tumor cells.  Filtered malignant ascites (1 mL) was 
first diluted to 4 mL with PBS buffer. Following the protocol described previously but 
without adding any free FR or KB cells, intrinsic FR+ cells and free FR were captured and 
fluorescently stained for identification and quantification. Once again, only those cells 
showing folate-FITC+, DAPI+ and anti-CD45- were scored (those cells that appeared 
triple-positive, i.e. folate-FITC+, DAPI+ and CD45+, were excluded from scoring). We 
captured 43 FR+ cells and measured 940 pM of FR from the diluted sample (i.e., 3.8 nM 
FR for the original sample, Figure 2.17). 
 
Figure 2.17. Example of fluorescent and reversed bright images from ascites sample. Note: the fluorescent image, i.e. (a. FL), was enhanced for display.   
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Using the free FR concentration along with the calibration data in Figure 2.14, the 
original number of FR+ cells present in the 1 mL of ascites can be estimated to be around 
101.  
To verify the results obtained using our system, FR concentration and number of FR+ 
cells present in the same ascites sample were also determined using ELISA and flow 
cytometry respectively. An ELISA kit for FR measurement was purchased from R&D 
system (Human FLOR1 Quantikine ELISA Kit, DFLR10). Following the protocols 
provided by the vendor, various concentrations of standard folate receptor included in the 
kit were first used to generate a reference curve. Ascites samples (200 µL) were diluted by 
100-fold and then 50 µL of diluted sample was measured based on the reference curve. The 
resulting FR concentration of the diluted ascites was measured to be 44.7 pM, which yields 
an FR concentration of 4.5 nM in the original ascites. This value is in reasonable agreement 
with the FR concentration measured by our system (3.8 nM). 
To detect FR+ cells in the ascites sample using flow cytometry, a total volume of 1 mL 
of ascites was first diluted to 2 mL with PBS buffer and separated into 2 tubes. Following 
that 10 µM of folate-FITC was introduced and incubated for 30 minutes to stain FR+ cells. 
All mixtures were then centrifuged and the supernatants were aspirated. The cell pellets 
were suspended in 250 µL of PBS buffer before introducing into a flow cytometer (BD 
Biosciences, ACCURI C6). The total number of folate-FITC+ cells was 167, in comparison 
with what we estimated using our system (101 cells). The difference could be attributed to 
the following reasons: (1) In our system we observed and excluded some triple-positive 
cells (folate-FITC+, DAPI+, and CD45+), which would normally be counted by a flow 
cytometer that simply scores all FITC+ cells. (2) The calibration curve in Figure 2.14 was 
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obtained for a specific type of cell that has a high expression of FR and hence can result in 
underestimating the number of other cells if they have a weaker expression of FR. (3) Since 
the concentration of target cells sought is relatively small (only some 100 within some mL), 
it is possible that two separate volumes, even if they come from the same original sample, 
may not contain exactly the same number of cells. Given these possibilities, the difference 
in the number of cells estimated in the two independent experiments is reasonable.   
2.5 Discussion 
In Chapter 2, a relatively simple immunomagnetic system capable of simultaneous 
detecting free molecules and whole cells was presented. The concept was demonstrated by 
applying the system to detection of free FR molecules as well as FR+ cells. The optimal 
flow rate was found to be 3 mL/min based on a computational model, and the system was 
characterized using this flow rate by detecting both molecular and cellular targets spiked 
in cell culture medium. The dynamic range of FR detection was found to be between 10 
pM and 100 nM; whereas the detection yield of KB cells was found to be dependent on the 
FR concentration due to a competition effect between both targets. Therefore, a calibration 
curve was obtained to use the number of cells captured on the chip surface along with the 
measured FR concentration to estimate the number of cells in the original sample fluid. We 
also showed the concurrent measurement of FR and KB cells spiked in healthy blood, 
which demonstrates the potential of this system in clinical applications. Finally, we applied 
this system to the analysis of a bodily fluid obtained from a cancer patient, where we 
detected free FR as well as FR+ cells endogenously present in the ascites fluid of an ovarian 
cancer patient. The results were further confirmed with commercial tools including flow 
cytometry and ELISA. 
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The concept, on which this system is built, is generic and versatile, and hence the same 
principles could be applied to detection of a wide range of cells and molecular biomarkers 
present in various bodily fluids. Adjustments in antibody, bead type (magnetic content, 
dimension) as well as experiment conditions (e.g. temperature, incubation time, flow rate) 
enable this system to capture different cell and molecule targets.  
The system however places an inherent limit on the number of beads that can be used. 
For many applications, such as rare cell detection, the number of beads needs to be 
maximized in order to capture as many of the target entities as possible. However, since 
both whole cells and free beads are collected on the same surface, a significant increase in 
number of beads introduces the danger of covering up the cells and making their 
recognition challenging and sometimes impossible. Hence, due to the lack of spatial 
separation beads from cells, this system is limited to relatively small sample volumes (and 
hence relatively low number of beads). Therefore, an improved system, which has the 
capability to process large number of beads (2-3 times of the beads used in first generation 
system) is needed. Such a system can separate cell-bead complex from free beads and even 




CHAPTER 3. SECOND-GENERATION SYSTEM FOR CTC DETECTION 
3.1 Introduction 
In this chapter, the second-generation system is presented as the improved version of the 
first-generation system. Similar to first generation system, second generation system 
employs immunomagnetic separation and parallel flow to capture targets from sample fluid. 
However, in order to overcome the inability of the first-generation system in separating 
cells from smaller entities (i.e. free beads), a micro-aperture chip composed of an array of 
micro-apertures (8 µm diameter) is incorporated as the size filter between the top and the 
bottom chambers (Figure 3.1 (a)) to sort out free beads into the lower chamber. Even 
though the ultimate goal of the thesis is to achieve concurrent detection of both cellular and 
molecular targets, Chapter 3 mainly focuses on the more challenging aspect of cell 
detection. Therefore, in this chapter the second-generation system is developed and applied 
for on-chip isolation and detection of CTCs from patient samples. 
As mentioned in Introduction, CTCs are rare cells present in the blood of cancer patients. 
They are shed from both primary and metastatic tumors and are believed to play a key role 
in cancer progression (e.g. indicators of metastatic disease and recurrence after surgery) 
[73-77]. The CTC count has been reported to correlate with overall tumor burden, and 
hence CTCs have been proposed as a biomarker for monitoring disease progression and 
response to therapy [23, 78-80]. Another major advantage of CTCs is that they can be 
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further interrogated after detection. For example, sequencing of the genome and 
transcriptome could reveal mutations or quantitate gene expression. The detected cells also 
have the potential to be cultured, grown and tested with different combinations of 
chemotherapeutic agents for drug discovery and personalized medicine. Thus, CTC 
detection is of great significance in early diagnosis of cancer, prognosis and therapy 
evaluation. 
The general detection strategy for the second-generation device is demonstrated in Figure 
3.1 (a). The sample mixture, pre-incubated with magnetic particles functionalized with 
antibodies against targets, is introduced into the top chamber using a high volumetric flow 
rate. A permanent magnet (the same one used in the first-generation system) positioned 
beneath the device provides the magnetic field to pull the targets bound to magnetic beads 
toward the micro-aperture chip. The free beads, owing to their smaller size (~1 µm), are 
drawn down to the bottom chamber through the holes. On the other hand, the target cells 
bound to beads are retained on the micro-aperture chip due to their relatively larger size 
(15-20 µm). The cellular targets are then subjected to fluorescent microscopy for 
quantitative analysis: the cells are identified and counted on chip surface in the top chamber 





Figure 3.1. (a) 3D schematic graph of the micro-aperture chip system; (b) SEM image of captured cells on chip surface. 
The operation process is illustrated in Figure 3.2. Cells tagged by antibody-conjugated 
magnetic beads are captured by means of an external magnetic field in the fluid device, 
similar to that in the first-generation device. But unlike the first-generation system, here, 




into the upper chamber with the smaller free bead complexes passing through the micro-
aperture holes into the lower chamber (Figure 3.2(a)). Often, many free magnetic beads 
still remain on the chip surface if they do not initially find an aperture to pass through. 
To alleviate this problem, a secondary, smaller magnet is situated on the top of the 
fluidic chamber in a stable orientation where it is attracted by the larger magnet in 
the bottom. The second magnet is subjected to an oscillating horizontal motion 
(Figure 3.2(b)) which perturbs the horizontal magnetic force applied on the beads 
and therefore guides them to adjacent apertures. The captured cells are then analyzed 
using immunofluorescence while they are still on the chip surface for identification 
and enumeration (Figure 3.2(c)). 
 
Figure 3.2. Flow of detection and enumeration of CTCs. 
Although at this stage only cells (and no molecules) were targeted, this system has been 
extensively characterized and examined in its capability to perform high-throughput, high-
purity detection, using large number of beads and multiple antibodies for high detection 
yield. Such optimization and validation constituted the first step to achieving the version 
that performs concurrent detection of both cells and molecules (which is the topic of 
Chapter 4). There are multiple advantages of the micro-aperture system over the single-
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layer system. Larger number of beads can be used to realize multiplex assay as well as to 
increase cell detection yield. As shown in Figure 3.3, using a single-chamber prototype 
(Figure 3.3 (left)), cells (KB cells) and beads could be simultaneously captured on a glass 
slide. However, due to the inability to separate the larger cell-bead complexes from beads, 
the ability to perform quantification was limited. Captured cells were occasionally buried 
under large bead accumulations (Figure 3.3 (Left)) and could thus not be easily counted 
via bright-field or fluorescence microscopy. As a result, relatively small number of beads 
had to be used, which could be a limiting factor in rare cell detection where every cell is 
precious and should not be missed due to scarcity of beads used. Moreover, since beads are 
separated into the bottom layer, during quantitative analysis (e.g. cell enumeration) 
interference from those entities is efficiently reduced, therefore visualization and imaging 
could be improved, purity of the captured cells can be enhanced, and the overall versatility 




Figure 3.3. Bright-field images on the left are for the single-chamber prototype containing a glass slide (viewed from the top). Images on the right are for the dual chamber system in which the micro-aperture chip surface (viewed from the top) is presented. The micro-aperture chip contains an array of ~8 µm diameter holes that appear dark. The top row of images corresponds to unused surfaces. The middle row shows the results of 80 µg of magnetic beads (incubated in culture media without cells) captured using both devices. The dark spots and roughened background for the glass chip are due to the beads, which contrast to the clear micro-aperture chip surface. The bottom row reveals the results of the same experiment as for the middle section but in the presence of target cells. Cells are identified with white arrows and appear dark due to being bound to antibody conjugated magnetic beads. The large cluster and bead-background on the glass surface limit the ability for accurate cell quantification. 
In this Chapter, breast cancer cell line MCF-7 cells were used as model of CTCs in both 
numerical analysis (as opposed to the KB cells used with the first-generation device) and 
the characterization experiments. The numerical model was developed using finite element 
analysis to help understand the physical operation of the system as well as to find the 
parameters for optimal system performance. The simulation was verified by spiking 70 
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MCF-7 cells pre-labelled with magnetic beads that were conjugated with antibodies 
against EpCAM (anti-EpCAM) into blood and study the relationship between the 
capture yield and flow rate. Then the system was characterized by detecting MCF-7 cells 
spiked into blood (from 0 to 110 cells/8 mL) to mimic analysis of blood samples obtained 
from cancer patients. Since MCF-7 highly expresses epithelial cell adhesion molecule 
(EpCAM), beads conjugated with anti-EpCAM (anti-EpCAM bead) are primarily used in 
the characterization experiment [81]. Finally, we demonstrate the utility of the system 
in detecting CTCs in blood samples collected from patients with non-small cell lung 
cancer (NSCLC, N = 38) and pancreatic cancer (PANC, N = 12). In CTC detection, 
a combination of different antibody beads was used in order to target multiple surface 
antigens on the surfaces of CTCs present in cancer patients’ blood samples [81-83]. 
3.2 Material and Methods 
3.2.1 Micro-aperture Chip 
The micro-aperture chip that contains an array of 8 µm apertures is placed parallel 
to the flow field in the chamber and serves as a size-based filter to separate whole 
cells (usually larger than 10 µm) from beads (around 1 µm) that are not bound to 
cells. The micro-aperture chips were produced using conventional silicon 
fabrication processes. The fabrication was performed on double-side-polished, 
<100> oriented intrinsic silicon wafers (4”) with a thickness of 550 µm, and the 
process flow was described in Figure 3.4 [84]. Photoresist (PR) AZ9260 
(MicroChemical) was first spin-coated onto the front side of the wafer following by 
a soft-bake at 110C for 10 minutes. Subsequently the PR was exposed and 
developed using an AZ400:DI water mixture (1:4 by volume). Deep Reactive Ion 
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Etching (DRIE, STS ASE) was used to selectively etch the silicon for 50 µm to 
create an array of cylindrical cavities. The PR was then removed using acetone and 
a layer of low stress silicon nitride (100 nm) was deposited on both sides of the wafer 
using low-pressure chemical vaper deposition (LPCVD, Protemp Horizontal 
Furnaces). Once again AZ9260 was spin-coated on the wafer, only this time on both 
sides, and was soft-baked. On the back side the PR was patterned to open up a 
window and the nitride was dry-etched using SF6 plasma (Plasma Tech RIE 80). 
Following that, the wafer was placed in a 40% potassium hydroxide (KOH) solution 
at 80C for wet etching of the silicon from the back side. The process was carefully 
monitored and stopped when silicon was etched till the bottom of the holes (when 
light could transmit through the holes). The remaining nitride layer was stripped by 
immersing the wafer into HF:DI water = 1:10. Finally, the wafer was cleaned using 
piranha solution (H2SO4:H2O2 = 3:7), ethanol and DI water to remove any residuals 
and particles. 
At the end of the fabrication process, 8 pieces of micro-aperture chips (40 mm by 
20 mm), each with a 9 mm by 3 mm porous area (50 µm thick) at the center, were 
obtained from a single 4” silicon wafer. Figure 3.4 (g) and (h) show SEM images of 




Figure 3.4. (a)–(f) Fabrication process flow and (g–h) SEM images of a fabricated micro-aperture chip. Each aperture is 8 µm in diameter. 
3.2.2 Experimental Setup 
Similar methodologies and materials (section 2.2.1) were used to configure the 
experimental setup. A fluidic chamber was first constructed by placing a layer of 
polydimethylsiloxane (PDMS, ~2 mm-thick) on a micro-aperture chip as a spacer 
and covered with a 1 mm-thick glass slide. The inlet and outlet of the fluidic chamber 
were opened on the cover slide. The dimension of the fluidic channel that encloses 
the porous area was defined by patterning the PDMS using a laser cutter (Universal 
Laser Systems, VLS 3.60) to have a 30 mm by 3.8 mm grove. The bottom of the 
micro-aperture chip was also sealed with a thin layer of PDMS coated on a 
transparency film (3M PP2500). The thickness of the PDMS-transparency film 
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complex was 0.1 mm. The assembled fluidic chamber was mounted on a hollow 
acrylic stand (shown in Figure 3.5(b)), in which a neodymium permanent magnet 
(K&J Magnetics, grade N52) could be inserted to provide a magnetic field. The inlet 
of the chamber was connected to the fluidic sources while the outlet was connected 
to a peristaltic pump (Ismatec ISM596B) and drained into a waste container or a 
collection tube (Figure 3.5 (c)). 
 
Figure 3.5. (a) A SEM image of a fabricated micro-aperture chip. (b) A picture of the microfluidic chamber assembly and (c) the experimental setup. 
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3.2.3 Experimental Procedures 
Detecting MCF-7 cells spiked into blood. We performed an initial characterization of the 
system by detecting known number of cells spiked into healthy human blood. A series of 
suspensions were prepared by spiking 0 to 110 MCF-7 (breast cancer cell line) cells into 8 
mL of blood collected from healthy donors under an approved IRB protocol (8 mL is the 
volume of a typical blood collection tube). The spiked blood samples were first treated 
with a red blood cell (RBC) lysis buffer (G-Biosciences) followed by centrifugation to 
remove the supernatant. The remaining cells were re-suspended in 1.5 mL of phosphate 
buffered saline (PBS, Invitrogen) and incubated with 4 μL (40 μg) of anti-EpCAM beads 
at 4 °C for 1 hour. The sample was then circulated in the fluidic chamber (with the bottom 
magnet in place) at a flow rate of 2 mL/min for 3 minutes, which was followed by washing 
with 3 mL of PBS solution. The captured cells were fixed on the chip and subjected to 
immunofluorescence analysis to identify and enumerate the MCF-7 cells. 
CTC detection in blood samples of NSCLC and PANC patients. Patients with advanced 
NSCLC and PANC were recruited for this study under an approved IRB protocol. Blood 
samples from 38 NSCLC and 12 PANC were collected. An 8 mL blood sample from each 
patient was either divided into 2 equal volumes of 4 mL s or used as a single 8 mL entity 
for examination. A combination of anti-EpCAM, anti-EGFR and anti-VMT beads (1 : 1 : 
1) were used with the NSCLC samples; and a combination of anti-EpCAM and anti-CEA 
beads (1 : 1) were used with the PANC samples. A group of beads was functionalized with 
only one type of an antibody. Multiple bead groups, each containing a different antibody 
were then added into the sample mixtures for incubation. The rest of the protocol was the 
same as that used in the detection of MCF-7 cells spiked into blood. 
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Blood sample collection and preparation. Blood donated by healthy volunteers as well 
as NSCLC and PANC patients was collected in BD Vacutainer tubes with additives of 
either acid citrate dextrose (ACD) solution A or sodium polyanethol sulfonate (SPS). Blood 
samples were kept at 4 °C starting immediately after collection until the detection process 
which occurred within 12 hours of collection. 
Preparation of magnetic beads conjugated with antibodies. Antibodies against EpCAM, 
EGFR, CEA and VMT were separately conjugated to magnetic beads freshly before 
detection. Biotinylated polyclonal antibodies against human EpCAM and CEA were 
purchased from R&D systems. Biotinylated monoclonal antibodies against human EGFR 
and VMT were purchased from Abcam. Streptavidin conjugated superparamagnetic beads 
with 1 μm diameter were obtained from Sigma Aldrich. We saturated the beads (20 μL, 10 
mg/mL) with excess amounts of antibodies (10 μL, 0.2 mg/mL) in PBS at room 
temperature for 1 hour, followed by rinsing with PBS three times on a magnetic stand and 
re-suspending in PBS. 
Cell culturing and preparation of cell suspensions. The breast cancer cell line MCF-7, 
obtained from American Type Culture Collection (ATCC), was cultured in Eagle's 
Minimum Essential Medium (EMEM, ATCC) with 0.01 mg/mL bovine insulin (Sigma-
Aldrich) and 10% fetal bovine serum (FBS, Gemini Bio Products). Cultured cells were 
harvested using Trypsin-EDTA (Invitrogen), and were re-suspended and diluted in culture 
media immediately before cell detection experiments. The original cell concentrations were 
determined by placing 3 μL of the cell suspension on a glass slide to count the cells using 
a bright field microscope and calculating the average from 4 measurements. The cell 
suspension was then spiked into blood to achieve the desired concentrations. 
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Immunofluorescence analysis. Cells captured on the micro-aperture chip surface were 
first fixed using a 4% PFA solution in PBS and then labeled fluorescently while the micro-
aperture chip was in the fluidic chamber. Anti-pan Cytokeratin monoclonal antibodies 
conjugated with FITC (anti-CK-FITC, Abcam, USA), anti-CD45 monoclonal antibodies 
(to rule out white blood cells) conjugated with phycoerythrin (anti-CD45-PE, Abcam, 
USA), and DAPI to verify nucleated cells (Sigma-Aldrich, USA) were introduced into the 
chamber at the same time and incubated for 1 hour at room temperature to label the cells. 
After washing away the unbound antibody-dye with 3 mL of PBS, the micro-aperture chip 
was inspected while still in the fluidic chamber using a fluorescent microscope (ECLIPSE 
80i, Nikon) with a Fiber illuminator (C-HGFI, Nikon). 
3.3 CTC Detection 
3.3.1 Modeling and Simulation 
The micro-aperture chip system was modeled and simulated following the same 
principles and procedures described in Chapter 2. In this section, we first investigated the 
system’s ability to capture cells. We primarily studied the effects of flow rate on the 
trajectory of cells within the fluidic chamber when they are bound by various numbers of 
magnetic beads. Then we investigated the lateral movement of the free beads on the micro-
aperture chip's surface resulting from the motion of an additional magnet situated on the 
top of the fluidic chamber. 
Detection mode. We simulated a scenario where certain number of MCF-7 cells, each 
bound with a given number of beads (1-10 beads/cell), flow though the fluidic chamber 
under the influence of a high volumetric flow rate that varies from 1 to 5 mL/min. The 
dimensions of the fluidic chamber used in the simulation were (L×W×D = 30×3.8×2.0 mm), 
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which are defined by a PDMS spacer in the fluidic chamber. The experimental parameters 
yield a Reynold's number of 4.58 indicating that the flow in the chamber is in general 
laminar. To simplify our simulation, we assumed that the porous structure does not have 
any significant effects on the bulk fluidic field. Meanwhile we keep all the assumptions 
mentioned in Chapter 2.  
The forces acting on a cell–beads complex in the chamber included the magnetic force, 
the drag force induced by the flow, gravity, and the buoyant force. We further assumed that 
the magnitude of the magnetic force acting on each cell–bead complex is proportional to 
the number of the beads bound to that particular cell, since this force acts directly on the 
beads, and not on the cells themselves. The magnetic force ܨ௠ሬሬሬሬԦ , which is one of the 
dominant forces in the system, can be expressed by [65, 66]: 
ܨ௠ሬሬሬሬԦ = N ௏ౘఞଶఓబ ∇(ܤሬԦ ∙ ܤሬԦ)                                                                                (3.1) 
where N is the number of beads attached to a cell; ୠܸ is the volume of a single bead (5.24 
× 10−19 m3); χ the effective volumetric magnetic susceptibility (2.7 unitless); ߤ଴  the 
vacuum permeability; and the magnetic flux density (produced by the N52 magnet), which 
is shown in Figure 3.6 (a). The resulting magnetic force applied on a single bead at the 
detection surface of the micro-aperture chip is shown in Figure 3.6 (b), where the green 
dashed line represents the magnitude of the vertical force (negative indicates a downward 
force) while the blue solid line represents the magnitude of the longitudinal force (positive 
indicates a force to the right). According to the results shown in both Figure 3.6 (a) and (b), 
magnetic particles tend to accumulate above two edges of the magnet because the lateral 
(x-direction) magnetic force concentrates particles in the two edge areas. 
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The fluid drag force FୢሬሬሬሬԦ, the other dominant force, acting on a cell–bead complex is given 
by [65, 66]:  
FୢሬሬሬሬԦ = 6πηr୮(UሬሬԦ − V୮ሬሬሬሬԦ)                                                                                           (3.2) 
where η is the fluid dynamic viscosity (2.5×10−3 kg m−1×s for processed blood sample); rp 
the radius of particle (5 μm for a MCF-7 cell); UሬሬԦ the velocity of fluid; and V୮ሬሬሬሬԦ the velocity 
of particle. 
The gravitational force applied on a complex is: 
F୮ = m୮gሬԦ                                                                     (3.3) 
where gሬԦ is the gravitational acceleration and mp is the mass of the cell–beads complex. The 
average mass of a dry MCF-7 cell, which is approximately 30% of the original mass, was 
measured to be 0.43 ng using a cantilever-based resonator [67]. 
The mass of a single magnetic bead with 1 μm diameter is around 1 pg. Hence the mass of 
a single cell bound with N beads is 1433 + N pg. 
The buoyant force can be expressed by: 
F = −gρܸ                                                                      (3.4) 
where ρ is the density of the fluid (~1000 kg m−3) and V is the volume of a cell–beads 
complex, which is approximately 5.24 × 10−16 m3. 
The contribution of gravitation (~14 pN) and buoyancy (~5 pN) are relatively small, yet 
their inclusion in the model is straightforward. Applying the Newton's second law yields: 






Figure 3.6. (a) The simulated magnetic flux density pattern of a N52 magnet and (b) the corresponding magnetic force applied on a single bead in the fluidic chamber. The green dashed line shows the magnitude of the vertical force while the blue solid line indicates the magnitude of the horizontal force. (c) Illustration of simulated trajectories of cell–beads complexes in the fluidic chamber. 
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We applied the particle tracing module in COMSOL to solve for the velocity and the 
displacement of the cell–beads complexes (as demonstrated in Figure 3.6 (c)). Based on 
the obtained trajectories the percentage of the cell–beads complexes reaching the micro-
aperture chip surface was estimated. 
To accomplish this, we first experimentally determined N (Equation (3.1)), and used it 
in our computational model to study the effect of flow rate on the rate with which the cells 
encounter the surface of the chip. 
To understand the extent of the specificity in the binding of beads, a study was carried 
out on how anti-EpCAM beads bind to MCF-7 cells as well as non-specifically to WBCs. 
This characterization is important since WBCs are the main contaminants in this assay and 
their presence on the chip surface hinders both the enumeration process, as well as the 
purity of the CTCs acquired for downstream analysis. Around 200 MCF-7 cells, as well as 
white blood cells (WBCs) isolated from 4 mL of healthy blood were first suspended in two 
separate tubes, added to 1.5 mL of PBS buffer, and incubated with 4μL (40μg) of anti-
EpCAM beads at 4°C for over 1 hour. The cells were aspirated using a micro-pipette, 
transferred onto a glass slide and the beads on their surfaces were counted using a bright-
field microscope with high magnification. The number of beads bound to each MCF-7 cells 
ranged from 3 to 63 with an average of 16.8 beads per cell, while majority of the WBCs 
(>99%) did not bind to any bead at all. For those WBCs that did bind to beads, the number 
of beads found on each WBC ranged from 1 to 19 with a mean of 2.3 beads per cell. The 
distribution of number of beads on each cell group is shown in Figure 3.7 (a) (the relative 
frequency for WBCs was calculated only for those that bound with beads). The histograms 
of MCF-7 and WBCs overlapped mainly when N<10. Figure 3.7 (a) also shows that around 
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90% of the MCF-7 bound to at least 7 beads, while around 90% of the bead-bound WBCs 




Figure 3.7. (a) Histograms in semi log-scale showing distribution of number of anti-EpCAM beads bound on MCF-7 cells and white blood cells (WBCs). All MCF-7 cells bound to at least 3 beads, while over 99% of WBCs did not bind to any beads. The relative frequency was calculated only for cells that bound to beads. (b) Simulated chip surface encounter rate of 100 cell–beads complexes vs. the flow rate. (c) Capture yield of pre-labeled MCF-7 cells (with beads) spiked in blood vs. the flow rate. Error bars indicate standard deviations from 3 measurements. 
Using this information, we simulated the trajectories of bead-bound cells under the 
influence of flow rates ranging from 1 to 5 mL/min. Figure 3.7 (b) shows the effect of flow 
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rate on discriminating cells based on the number of beads they are bound to. According to 
Figure 3.7 (b), the optimal flow rate of our system is about 2 mL min-1 since at this flow 
rate, cells bound with 7 or more beads (90% of cancer cells) encounter the chip surface 
with a probability of 96% or greater. At the same time, cells that are bound to fewer than 
4 beads (90% of bead-bound WBCs) encounter the chip surface with a much lower 
probability. This relatively simple computational model only accounts for a cell's motion 
until it encounters the chip surface and not what happens afterwards (e.g. bouncing off, 
colliding with other particles, or moving on the chip surface etc.). However, it effectively 
confirms the basic relationship between the flow rate and the number of beads and suggests 
that an optimal choice of a flow rate could help reduce capturing unintended cells that are 
bound to small number of beads non-specifically without significantly hampering the 
specific capturing of cancer cells, and that too low a flow rate (e.g.<2 mL/min) could 
increase the capture of unintended cells without a significant improvement in the detection 
of specific cancer cells. Despite a negative 5% offset in the capture yield that is presumably 
due to imperfections in affinity or centrifugation after the RBC lysing step, the 
experimental result in Figure 3.7(c) is in good agreement with the simulated data in Figure 
3.7(b) and confirms the optimal flow rate suggested by the simulations. 
Dual-magnet mode. The magnetic force attracting bead-bound cells down to the chip 
surface results in a number of free beads that land between the apertures and therefore 
remain on the chip instead of being immediately cleared out. A simple modification to the 
setup clears these free beads out by perturbing the total magnetic field with a second 
magnet (whose polarity is aligned for attraction to the primary magnet) situated on top of 
the chamber. Manually moving this magnet horizontally in an oscillatory fashion perturbs 
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the horizontal magnetic force on the beads and hence leads them to the bottom chamber 
through the apertures. 
 We built a computational model in order to quantitatively explain the effects of this 
modification. The analysis was performed under the assumption of zero flow rate since it 
focuses on the beads that have already been captured on the chip surface. Figure 3.8 (a) 
shows the magnetic flux density distribution in the chamber when the top magnet 
(3/16”×3/16”×3/16”) is aligned with the center of the bottom magnet (1/4”×1/4”×1/4”), as 
well as when it is located to the left of the bottom magnet. The corresponding magnetic 
forces applied on a bead with respect to its position on the chip are shown in Figure 3.8 (b). 
The simulation result shows that the horizontal motion of the top magnet causes significant 
changes in the magnetic flux density distribution, which alters the magnetic force induced 
on the beads in the chamber, especially in the horizontal direction. As a result, the free 
beads located in between the apertures on the chip move horizontally along with the motion 
of the top magnet. We simulated the horizontal motion of a bead located on the surface of 
the central region of the chip and observed that a 3 mm sideways motion of the top magnet 
caused the bead to move by 150 µm which is sufficient to lead it to an aperture to be pulled 
down by the vertical magnetic force. Figure 3.8 (c) demonstrates the simulated motion of 
a bead located at the center of the micro-aperture chip. The bead reached an adjacent 
aperture and fell through it with only a 200 µm motion of the top magnet. Therefore, 
moving the top magnet by as much as a few millimeters should effectively clear out most 
of the free beads that do not initially coincide with an aperture (Figure 3.8 (d)(e)). It is also 
plausible that the dual magnet configuration can help clear out the unwanted bead-bound 






Figure 3.8. (a) The simulated magnetic flux density of the dual magnet configuration and (b) the corresponding magnetic force applied on a single bead in the fluidic chamber. (c) Schematic illustrating the motion of a bead located at the center of the micro-chip with respective to the movement of the top magnet. The 10 µm lateral displacement of the bead is resulted from the 200 µm lateral movement of the top magnet. The schematic was not drawn to scale. (d) (e) Micrographs of chip surfaces without and with the use of a second magnet after capture to clear out the free beads. Scale bars indicate 56 μm. 
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3.3.2 System Characterization by Detecting MCF-7 Cells 
Following simulation, the system's ability to recognize and capture tumor cells 
spiked into blood samples of healthy humans was experimentally investigated. We 
spiked known numbers (0, 8, 10, 20, 30, 40, 50, 60, 70, 100, and 110) of MCF-7 
cells into 8 mL of blood, and captured them using anti-EpCAM beads.  
Based on the computational study and the experiments discussed above, ideally 
around 95% of the spiked tumor cells could encounter the chip surface when the 
sample mixture flows through the chamber at 2 mL/min. However, the actual 
detection yield is expected to be lower because of a number of factors. For example, 
some cells could be lost during centrifugation after RBC lysing step or during 
incubation with beads, also the binding efficiency between MCF-7 cells and 
antibody-beads could be impeded due to the complexity of the binding environment. 
It is therefore important to minimize additional losses once the bead-bound cells are 
introduced into the chamber. The high flow rate capability of our system allows us 
to quickly circulate the sample mixture multiple times and help maximize the 
chances of recovering a cell that may have skipped the chip surface during its first 
pass. We therefore circulated the sample at 2 mL/min for 3 minutes, equivalent to 
passing it through the chamber 4 times over. 
Using fluorescence analysis as described in section 3.2.3, enumeration of the 
detected tumor cells was performed manually by capturing images of different 
segments of the chip surface and counting the cells in each segment. A plot of the 
number of cells detected vs. number of those spiked is shown in Figure 3.9 (b). The 
slope of the linear fit shows that the system can detect cells with an 89% detection 
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yield and the fairly linear nature of the relationship shows that the system robustly 
delivers this efficiency at a wide range of cell concentrations – relevant to rare cell 
detection. 
 
Figure 3.9. (a) Bright-field and fluorescent images of cells detected from MCF-7-spiked blood. MCF-7 cells are stained with CK-FITC and thus show green fluorescence; while WBCs are stained with CD45-PE and show red. Scale bar indicates 24μm. The contrast of the fluorescent images has been enhanced artificially. (b) Number of MCF-7 cells detected vs. number of those spiked in blood. 
3.3.3 Detection of CTCs from Cancer Patient Samples 
After characterizing the system by detecting MCF-7, we detected CTCs in the 
blood samples obtained from patients with advanced cancer. Blood samples 
collected from a total of 50 patients with non-small cell lung cancer (NSCLC, n = 
38) and pancreatic cancer (PANC, n = 12) were tested using our system. All of the 
patients had stage IV metastatic diseases and 20 of the NSCLC patients and 5 of the 
PANC patients had not received systemic treatment. 4 to 8 mL of blood from each 
patient was examined following the same protocol used in detection of MCF-7 cells 
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spiked in blood except for the choice of the antibody-beads. Unlike the cancer cell 
lines that are always cultured in a simple and controlled laboratory environment, the 
CTCs from patients may vary in their expression and affinity for the EpCAM 
antibody. 
We used a combination of beads conjugated with different antibodies to target 
multiple antigens overexpressed on CTCs. A combination of beads conjugated with 
anti-EpCAM, anti-EGFR and anti-VMT at a ratio of 1:1 was used to test NSCLC 
samples; while a combination of anti-EpCAM and anti-CEA beads (1:1) were used 
for PANC samples. The anti-EGFR and anti-CEA were used to target an extra 
antigen (other than EpCAM) that could possibly be overexpressed on CTCs in lung 
and pancreatic cancers, respectively. On the other hand, anti-VMT beads were used 
to target any CTCs that may be going through epithelial-mesenchymal transition. 
The number of CTCs per 8 mL of blood of each patient is shown in Figure 3.10. 
We identified CTCs in 49 of 50 patients. Only one PANC patient that had received 
chemotherapy recently did not show any CTCs. The number of CTCs detected 
ranged from 2 to 122 per 8 mL for NSCLC and 0 to 42 per 8 mL for PANC, resulting 
in a mean and standard deviation of 39 ± 32 CTCs/8 mL for NSCLC and 26 ± 11 
CTCs/8 mL for PANC.  
We further grouped the number of CTCs detected from patients who had received 
systemic cancer treatments as well as from those who had not and plotted them in 
Figure 3.10. On average we detected 55 CTCs in the blood samples of untreated 
NSCLC patients and 21 in those of treated ones; meanwhile, the average CTC counts 
of the untreated and treated PANC patients are 31 and 22. A student t-test analysis 
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on the two groups of NSCLC patients revealed a p-value of 0.00045, indicating a 
statistically significant difference between the CTC counts of the two groups. On 
the other hand, presumably due to relatively smaller sample size, the p-value of the 
average count between the treated and untreated PANC data is 0.13114 indicating 
that the difference is statistically insignificant. 
 
Figure 3.10. (a) Histograms showing number of CTCs detected from each of the 50 patients. (b) The mean, standard deviation and p-value of number of CTCs detected from treated and untreated patients. 
3.4 Discussion 
In Chapter 3, a second-generation system featured by a micro-aperture chip was 
presented for CTC detection. This system integrated a micro-aperture chip to spatially 
separate captured cells from free beads. The micro-aperture chip was fabricated using 
conventional clean-room manufacturing techniques (photolithography, DRIE, plasma Etch, 
wet Etch). Cells captured can be imaged and enumerated directly on the micro-aperture 





molecules, finite element analysis (FEA) tool was used to analyze factors such as flow rate, 
number of beads per cell, as well as dual-magnet mode. By tuning the flow velocity, a 
working window has been found to efficiently detect cancer cell without nonspecifically 
capturing WBCs. The optimal flow rate for CTC detection was found to be 2 mL/min based 
on a computational model that was also verified experimentally. We have observed that in 
general MCF7 cells bind to fewer beads than KB cells and hence the lower optimal flow 
rate of 2 mL/min (vs. 3 mL/min) is reasonable.  With the optimized flow rate, 89% of the 
MCF-7 cells spiked in 8 mL of blood were detected. This system was further applied to 
process clinical samples obtained from NSCLC and PANC patients using combination of 
antibody-beads and have detected CTCs in all 38 NSCLC patients and 11 of 12 PANC 
patients. Moreover, the data demonstrated a statistically significant difference in the 
number of CTCs between treated and untreated NSCLC patients, which warrants further 
analyses and studying of the correlation between the CTCs detected by this system and the 
overall tumor burden. Those results confirmed that the second-generation system, with a 
stronger ability to process large amount of beads, achieved a higher cell detection yield 
compared to the first generation system. Also, interference induced by free beads can be 
significantly minimized so high-quality enumeration of captured cells can be realized. 
Another major advantage second-generation system over the first-generation system is 
more than two types of analytes can be detected to further improve the detection efficiency. 
Therefore, in Chapter 4 we will further exploit this system’s capability in simultaneously 




CHAPTER 4. SECOND-GENERATION SYSTEM FOR SEPARATION AND DUAL DETECTION OF PROSTATE CANCER MARKERS 
4.1 Introduction 
In previous chapter, the development of the micro-aperture (i.e. second-generation) 
system, and its testing in the context of detecting whole cells was described. This chapter 
focuses on further development and adaptation of the same system to detection of both 
cells and molecules from the same sample and at the same time.  As described before, 
detecting both cellular as well as molecular markers of cancer can provide more complete 
and complementary information about the progression of the disease. To put our device 
into context, we chose prostate cancer where dual molecular/cellular detection can be 
especially useful. Prostate cancer is the most commonly occurring cancer for men in the 
United States. In 2016 alone, the estimated numbers of newly diagnosed cases and deaths 
due to prostate cancer are 180,890 and 26,120, respectively [85]. In an effort to reduce the 
impact of prostate cancer on society, there has been a major push towards early detection 
strategies to help stop the disease before it becomes life threatening. Critical to this effort 
is the discovery and validation of biomarkers (e.g. proteins, DNA, metabolites, cells, etc.) 
which is of great significance not only because these analytes are important for early 
diagnostic screening tests, but also due to their roles in establishing prognosis and 
monitoring response to therapy, among other uses [2, 6-9]. While multiple biomarkers have 
been investigated for the detection of prostate cancer, including prostate specific membrane 
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antigen (PSMA), micro-RNA, and survivin, the most commonly used biomarker for 
diagnosing prostate cancer is the protein, prostate specific antigen (PSA) [86-88]. PSA is 
detectable via a number of available and highly sensitive assays [89]. However, the 
extensive use of diagnostic screening tests based primarily on PSA are controversial, so 
much so, that in 2012 the United States Preventive Task Force concluded that the risks of 
such routine blood tests (e.g. unneeded surgery and radiation) outweighed the benefits of 
early detection and thus recommended reduced testing [90]. This has led to the search for 
additional biomarker candidates that can better stratify different disease states. 
CTCs or circulating tumor cells have been extensively studied and validated for use in 
prostate cancer [21, 22]. CTC biomarkers are commonly isolated via immuno-magnetic 
bead-based separation assays by targeting specific cell-surface markers such as EpCAM, 
cytokeratin, PSMA, vimentin, and others [91-94]. Prostate CTCs have recently been found 
to be correlated with a number of other recognized targets (e.g. lactate dehydrogenase, 
alkaline phosphatase, PSA) and used in combination for treatment monitoring and survival 
prediction of prostate cancer patients [95, 96]. For example, the use of the CellSearch 
platform for CTC detection combined with a real-time quantitative polymerase chain 
reaction (RT-qPCR) assay enabled an approach consisting of CTC enumeration and stem 
cell gene expression analysis to be applied and used to determine the prognosis and predict 
treatment outcomes in a metastatic castration-resistant prostate cancer model [97]. This 
example demonstrates the need and advantage of developing biomarker panels via 
multiplexed target analysis. However, the widespread implementation of such multiplex 
analysis requires overcoming several barriers and limitations [1, 2, 10-12]. These include 
inter-individual variability, reliability, sensitivity and specificity during analyte detection, 
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all of which have led to significant measurement deviations [98]. Additionally, multiple 
biomarker platforms are often employed to perform numerous individual tests, often at 
great expense, in order to provide sufficient reliable information for patient evaluation [13-
15, 92]. This has led to the need for high-throughput detection platforms capable of 
analyzing multiple biomarkers simultaneously from a single sample. 
Several commercial high-throughput platforms for multiplexed protein analysis are 
widely available (e.g. Luminex, MSD) and academic groups along with industry are 
actively pursuing methods for the detection and analysis of cancer cells (e.g. CTCs) from 
large sample volumes. However, it is not ideal to measure proteins or cells, separately, 
which is the case with most biosensor platforms [7, 37, 81, 99-103]. As the CTC capture 
and stem cell gene expression study above illustrated, valuable information can be gathered 
from both cellular and molecular biomarkers. Additionally, by more accurately correlating 
molecular biomarker concentrations in a sample fluid with specific cell populations present, 
which would be possible with a dual-detection platform, new biomarker panels could be 
developed to better describe a patient’s disease state and provide a more holistic analysis 
[29]. Analyzing a single sample for multiple target types – cells and molecules – should 
also lead to reduced sample-to-sample variation [104-106]. 
In Chapter 2, we introduced the first-generation system capable of concurrently detecting 
cellular and molecular markers, in high throughput, from a single sample fluid. This device 
utilized a glass slide integrated with a magnet for attracting cellular and molecular 
biomarkers bound to antibody-conjugated magnetic beads [107]. While this preliminary 
system successfully demonstrated the ability to simultaneously detect cellular and 
molecular targets from an ovarian cancer patient sample (ascites fluid), several limitations 
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were observed. As discussed in section 3.1 (Figure 3.3), these limits include captured cells 
being buried under bead clusters, which was exacerbated when higher bead concentrations 
were used. The clusters of beads on top of cells reduced the cell purity (especially for 
fluorescence imaging purposes) and the combination of captured cells and molecular 
markers, with any remaining beads, all on the same surface also reduced the ability to 
retrieve the cells for downstream analysis (e.g. genetic sequencing, culturing, etc). As the 
concentration of CTCs in patient samples are very low, the inability to increase the bead 
amount conversely affected the ability for multiplexed ligand targeting, which could be 
used for not only capturing additional protein/molecular analytes but also for increasing 
the number of CTCs detected. Therefore, in Chapter 3 we have developed the second-
generation system that combines rapid fluid flow with size-based separation to achieve a 
high-throughput immuno-magnetic detection platform and applied this system to capture 
CTCs from breast cancer patient blood. However, at that stage only the cell detection has 
been realized.  
In this chapter, we further develop the second-generation system for the simultaneous 
separation and detection of molecular and cellular targets. The new version divides 
magnetically captured cellular and molecular targets into upper and lower chambers, 
respectively, via the use of a silicon chip containing 6 µm diameter micro-aperture holes. 
Upon incubating a liquid sample with antibody-conjugated magnetic beads targeting 
desired cells and protein biomarkers, the sample is then flowed through the upper chamber 
of the device. The integration of an external magnetic force with the micro-aperture chip 
allows the larger cell-bead complexes (>10 µm) to be trapped on top of the chip, with the 
smaller protein-bead complexes (1 µm) and remaining beads passing through the micro-
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aperture holes into the lower chamber where the magnetic force holds them in place on a 
bottom surface. In this chapter, we decreased the micro-aperture size from 8 µm to 6 µm 
because we try to keep extremely small CTCs from being squeezed into the holes and 
dropping down to the lower chamber.      
As already mentioned in Chapter 3, there are multiple advantages of the new generation 
device over the first-generation system. First, due to the efficient elimination of non-cell 
complexed beads from the upper chamber, both captured cells and molecules can be 
analyzed separately without mutual interference [81]. The cells can be quantified directly 
on chip and then removed for further investigation. Protein-bound beads can be retrieved 
from the bottom chamber and analyzed using fluorescence-based detection or with other 
commercially available assays. Lastly, this design enables the use of higher bead 
concentrations. 
The detection strategy (Figure 4.1) is similar to what has been discussed in Chapter 
2. Super-paramagnetic streptavidin coated microparticles are first conjugated to 
their corresponding biotinylated polyclonal antibodies. A sample fluid containing 
spiked model prostate cancer “LNCaP” cells and prostate specific membrane 
antigen or “PSMA” protein (Figure 4.1 (a)) is then combined with the antibody 
conjugated-bead (anti-bead) mixture and incubated for 90 min using an end-over-
end rotator. 
The microfluidic device is divided into two parallel chambers separated by a 
micro-aperture chip composed of an array of 6 µm diameter micro-apertures 
(2.6×105 holes in total). Following sample incubation, the mixture is flowed through 
the upper chamber (Figure 4.1 (b)) at a flow rate of 2 mL/min and circulated for 4 
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min. A permanent magnet positioned beneath the device provides the magnetic field to 
pull the bead-bound cells and proteins, as well as free beads, towards the micro-aperture 
chip. The protein-bead complexes and free beads, owing to their smaller size (1 µm), can 
be drawn down to the lower chamber through the micro-apertures whereas cell-bead 
complexes, due to their larger size (>10 µm), are retained on top of the micro-aperture chip 
in the upper chamber. The cell and molecular targets, in the upper and lower chambers, 
respectively, are then subjected to separate fluorescence-based quantitative assays. The 
cells are enumerated on the chip surface. The protein-bound beads are retrieved from the 
lower chamber by introducing washing buffer with the magnet removed and then analyzed 
via fluorescence microscopy. 
 






Figure 4.1. Continued 
This chapter first presents the device assembly and operation, followed by numerical 
modeling. Next, multiple ligands conjugated to magnetic beads are investigated to achieve 
maximal cell capture yield. Using culture media, the limit of detection for PSMA as well 
as the performance in dual analyte capture is then determined. Finally, the potential of the 
device for clinical applications is demonstrated using diluted human blood spiked with 
PSMA and LNCaP cell targets, to mimic prostate CTCs and protein biomarkers from a 
patient sample. 
4.2 Materials and Methods 
In this chapter, we characterized the new device for dual detection using a prostate cancer 
model, PSMA free-protein and LNCaP cells, with two antibodies, anti-PSMA and anti-
EpCAM [108, 109]. EpCAM and PSMA cell surface markers have been previously used 
to isolate prostate cancer CTCs [110]. The LNCaP cell line is a commonly applied model 
for prostate cancer and has been shown to express both EpCAM and PSMA antigens on 
the cell surface, making it particularly relevant to our work [111-113]. As EpCAM is one 




cancers, its use with LNCaP cells also enables the device characterization to be more 
generalized to other diseases [114]. The cell-free PSMA protein was chosen due to its value, 
from an analytical perspective, to challenge the new device by using a free-protein 
target that is also on the surface of the cell, in combination with a ligand (EpCAM) 
specifically targeting only the cell itself. This contrasts with the scenario in which 
the free-protein and cells would be captured using completely different antibodies. 
While the presence of PSMA free-protein in circulation has been studied, the clinical 
significance of detecting PSMA alone for prostate cancer remains uncertain [115, 
116]. Thus, a method to simultaneously detect free-PSMA protein as well as prostate 
cancer cells might allow for new diagnostic value for PSMA.  
4.2.1 System and Device Assembly 
The microfluidic device consists of eight components: acrylic cover, acrylic stand, 
top fluid cover, bottom fluid cover, top fluid spacer (PDMS Spacer I), bottom fluid 
spacer (PDMS Spacer II), micro-aperture chip, and magnet. The assembling scheme 
is shown in Figure 4.2 (a). The top fluid chamber was constructed by placing a layer 
of PDMS (thickness ~1.0 mm) on the micro-aperture chip, to serve as a spacer, and 
then mounting a 1 mm-thick glass slide on top of it. A laser cutter (Universal Laser 
System, Inc. Professional Series) was used to define the dimensions (30 mm by 3.8 
mm) of the PDMS channel such that it enclosed the porous area (8560 µm by 2750 
µm) of the micro-aperture chip. The chip (thickness of 550 μm) with a porous area 
of 6 μm diameter micro-aperture arrays was fabricated following the procedures 
described in a previous publication [84]. The inlet and outlet for the upper chamber 
were formed by drilling holes through the glass slide using a diamond rotary bit. 
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Tubing was sealed in place with epoxy. The bottom chamber was constructed with 
another PDMS layer (thickness ~0.2 mm) containing a channel (30 mm by 3.8 mm) 
fabricated with the laser cutter. The lower channel was sealed using a transparency 
sheet (3M PP2500, 0.1 mm thick). For the transparency sheet, the inlet and outlet 
holes were fabricated using the laser cutter. The bottom inlet and outlet tubing was 
connected to plastic elbow fittings and glued to the holes of the transparency sheet 
using epoxy. The assembled components were then mounted on an acrylic stand 
containing three cut-out rectangular openings. The middle opening was for inserting 
the magnet while the two openings on both sides provided space for the inlet and 
outlet tubing to emerge from the bottom chamber. All acrylic components were 
modified using the laser cutter. The top acrylic cover also contained a wide cut-out 
to enable quantification of cells directly on the chip surface using a fluorescence 
microscope. 
 
Figure 4.2. Device assembly. (a) Exploded view of assembly scheme. (b) The assembled device. (c) SEM image of the micro-aperture chip containing an array of 6 µm diameter micro-apertures. 
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4.2.2 Device Modeling 
COMSOL was used to model the influence of the micro-aperture chip surface on 
the magnetic bead trajectories. This was performed to quantify the number of beads 
that pass through the micro-apertures into the bottom chamber while flowing the 
solution through the upper chamber of the device. All other simulation details, 
equations and conditions are similar to that in Chapters 2 and 3 [81, 107]. To 
simplify the modelling, only beads without cells were used for the simulations – the 
possibility of cells passing through holes via contortion or other shape modification 
was neglected. 
4.2.3 Experimental Setup 
As described in “System and Device Assembly”, two sets of inlets and outlets 
provided access to the top and bottom chambers. After priming the upper and lower 
chambers with PBS buffer, the bottom inlet and outlet were sealed. The top inlet 
was then connected to the sample source and the top outlet was connected to a 
peristaltic pump (New Era Pump Systems, NE-9000). This allowed the sample/bead 
mixture and buffer to only flow through the top chamber of the device. In order to 
retrieve and collect the protein-bead complexes from the bottom chamber for 
downstream analysis following an experiment, the top inlet and outlet tubes were 
sealed, the bottom inlet tube was connected to the washing buffer (PBS) and the 
bottom outlet tube was connected to the pump. With the magnet removed, the beads 




Prior to running any experiments, PBS-T (PBS containing Tween 20) plus bovine 
serum albumin (BSA) was used to block the solution-exposed surfaces of the device. 
The blocking solution consisted of 600 µL of 20x PBS-T (Thermo Fisher Scientific, 
USA), 400 µL of 30% BSA in PBS (Sigma, USA), and 11 mL of DI water. About 
200 µL of this solution was injected into the upper chamber of the device and 
incubated for 3 hours at room temperature. Both the bottom and top chambers were 
then flushed with PBS. 
4.2.4 Preparation of LNCaP Cells and PSMA Protein Solution 
LNCaP cells, purchased from American Type Culture Collection, were cultured in 
RPMI 1640 media (Gibco, USA) containing 10% fetal bovine serum (FBS, Gemini 
Bio Products). To harvest LNCaP cells, they were first released from a culture flask 
using a Trypsin-EDTA solution (Invitrogen) and then re-suspended in culture 
medium. The cell concentration was measured by taking 5 samples (each with a 
volume of 3 µL, ejected onto a microscope slide) and manually counting the cell 
number using a bright-field microscope to obtain the average. The cell suspensions 
were then subsequently spiked into 1 mL of medium (or diluted blood) to achieve 
the desired concentration. 
Recombinant human PSMA/FOLH1 protein (PSMA) was purchased from R&D 
systems and stored at -20℃ at a concentration of 0.5 mg/mL in PBS. PSMA was 




4.2.5 Preparation of Antibody-coupled Magnetic Beads 
Biotinylated polyclonal anti-PSMA, anti-EpCAM, and anti-EGFR were all 
purchased from R&D Systems and stored at a concentration of 0.2 mg/mL in PBS. 
Prior to detection, the desired antibody was conjugated to micro-beads by incubating 
the antibody (10 µL) with streptavidin-coated 1 µm magnetic beads (20 µL, 10 
mg/mL, Sigma Aldrich) in phosphate buffered saline (PBS) at room temperature for 
60 min on an end-over-end rotator. An excess amount of antibody was used to ensure 
saturation of binding sites on the bead surface. Following incubation, the beads were 
washed 3 times with PBS using a magnetic stand (PerkinElmer, Germany) and then 
stored at 2 mg/mL. 
4.2.6 Detection of LNCaP Cells in the Absence of Free PSMA 
The device was initially tested with multiple antibody-conjugated magnetic beads 
to determine which ligands and quantity of beads provided the highest capture of 
LNCaP cells. The new device enabled the doubling of the 1 µm bead amount able 
to be used in an assay, from 40 µg in the previous design to 80 µg [107]. This was 
due to the ability to clear the excess beads into the lower chamber. In these 
experiments, ~100 LNCaP cells were spiked into 1 mL of culture medium. The 
spiked samples were then incubated with either 40 µg (20 µL) or 80 µg (40 µL) of 
antibody beads at room temperature for 90 min using an end-over-end rotator. If a 
single antibody was used then 20 µL or 40 µL of only that bead solution (2 mg/mL) 
was added. If two antibodies were used, then 20 µL of each antibody bead solution 
was added. The sample was then circulated in the upper chamber of the device (with 
92 
 
the bottom magnet in place) at a flow rate of 2 mL/min for 4 minutes followed by 
washing with 2 mL of PBS.  
Following detection, any free-beads which remained on the micro-aperture chip 
surface were gathered into the bottom chamber using a dual-magnet mode as 
discussed in Chapter 3 [81]. After that, with only the bottom magnet in place, the 
captured cells were then directly fixed on the chip using a 4% paraformaldehyde 
(PFA) solution in PBS followed by fluorescent tagging for confirmation. To label 
the cells, monoclonal antibodies against PSMA conjugated with PE (anti-PSMA-PE, 
Miltenyi Biotec, USA), anti-pan Cytokeratin monoclonal antibodies conjugated to 
FITC (anti-CK-FITC, Miltenyi Biotec, USA), and 4',6-diamidino-2-phenylindole 
(DAPI, Sigma-Aldrich, USA) were introduced into the chamber all at once and 
incubated for 30 minutes at room temperature. Unbound labels were washed out 
with 3 mL of PBS. The micro-aperture chip was then inspected while still in the 
microfluidic device, using a fluorescence microscope (ECLIPSE 80i, Nikon) 
containing a fibre illuminator (C-HGFI, Nikon), to count the captured cells and 
determine the capture efficiency.  
4.2.7 Detection of Free PSMA in the Absence of LNCaP Cells 
The detection of free-PSMA (without LNCaP cells) was performed identically to 
that above for LNCaP cells without PSMA but with the following modification. For 
these experiments, only PSMA was spiked (0 – 12.5 nM, 0 – 1000 ng/mL) into 1 
mL of culture media. Following detection, the dual-magnet mode, as described 
above, was used in order to gather PSMA-bound beads and free-beads into the 
bottom chamber. Both magnets were then removed and 1.5 mL of PBS was 
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introduced into the bottom chamber at a flow rate of 1.5 mL/min to wash out the 
beads, which were collected in a plastic tube.  
These beads were then analysed by flowing the collected suspension into a 
chamber containing a glass slide with a magnet placed underneath for immuno-
fluorescence analysis (Figure 4.3). Prior to analyzing the samples and in order to 
prevent non-specific binding of antibodies, a PBS solution containing 0.05% 
Tween-20 and 1% BSA was introduced into the single-chamber device and allowed 
to incubate for 3 hours at room temperature. The device was then washed with 2 mL 
of PBS at a flow rate of 3 mL/min. Retrieved beads were injected into the chamber 
and distributed over the chamber’s glass surface, and held in place by the external 
magnetic force. PSMA was subsequently stained with anti-PSMA-PE (1:20 dilution 
in PBS) and incubated under static conditions at room temperature for 30 minutes, 
followed by washing with 3 mL of PBS. Finally, the chamber was inspected using 
the fluorescence microscope for PSMA quantification [107]. 
 
Figure 4.3. Schematic diagram of single-layer system for bead-based molecule fluorescent imaging. 
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4.2.8 Dual Detection of LNCaP Cells and PSMA 
The combined detection of LNCaP cells and PSMA from culture media was 
performed next. Here, a series of suspensions were prepared by spiking ~100 LNCaP 
cells and PSMA with various concentrations from 0 to 12.5 nM (0 – 1000 ng/mL) 
into 1 mL of culture medium. The samples were then incubated using the optimal 
antibody bead composition and analysed according to the two previous sections. 
For detection in human blood, 1 mL of diluted blood (blood:PBS (1:3)) was 
prepared and used within 2 hours after being collected from healthy volunteers under 
an approved IRB protocol. Blood samples were first drawn into BD vacutainer tubes 
containing sodium poly(anethol) sulfonate as the anti-coagulant prior to being 
diluted. For these experiments, LNCaP cells and/or free PSMA (in addition to the level 
of PSMA naturally present) were spiked into each sample. Four conditions were tested: (1) 
a blank without any added target protein or cells; (2) ~27 added LNCaP cells; (3) ~27 added 
LNCaP cells and 50 pM (4 ng/mL) of PSMA. (4) ~54 added LNCaP cells and 1.25 nM 
(100 ng/mL) of PSMA. It should be noted that the spiked PSMA concentrations provided 
are relative to the 1 mL diluted sample volume.  
The diluted blood samples were then analyszd similar to that for dual detection from 
media but with the following modifications. Prior to fixing the cells using PFA but after 
removing the beads from the bottom chamber, red blood cell (RBC) lysis buffer (G-
Biosciences, U.S.A.) was introduced into the upper chamber and incubated for 5 min 
before rinsing with PBS. This was done in order to remove RBCs which were 
attracted to the magnet during the sample circulation step. Additionally, anti-CD45-
PE was added to the dye cocktail for cell labelling in order to differentiate any white 
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blood cells (WBCs) that might be present due to non-specific binding. Anti-PSMA-
PE was removed from the dye cocktail so it would not overlap with the anti-CD45-
PE signal due to their identical fluorescent labels (i.e. Phycoerythrin (PE)).  
4.3 Results and Discussion 
4.3.1 Modeling the Effect of the Micro-aperture Chip for Magnetic Bead Capture 
In previous chapters, we used simulations to investigate how flow rate and the 
number of beads bound per cell would influence the trajectories of cell-bead 
complexes in our microfluidic device [81, 107]. It was assumed in Chapter 3 that 
the micro-aperture chip functioned as a solid surface (without pores) with respect to 
its ability to capture bead-bound cells. Finite element analysis software (COMSOL) 
was used to simulate the magnetic field, flow field, induced magnetic force and fluid 
drag force, as well as the gravity and buoyant forces acting on cells and magnetic 
beads [81]. Here, we extended our characterization to account for the true 6 µm 
diameter micro-aperture array structure in order to determine the quantitative effect 
of the structure on the ability of protein-bead complexes and free beads to fall into 
the lower chamber of the device during sample flow.  
For this work, the magnetization effect of particles on one another, the difference 
between a protein-bound bead and a free bead, and the effect of pore-depth of the micro-
aperture chip on the bead were all assumed to be negligible. It was also assumed that the 
beads were randomly distributed over the inlet cross-section as they were introduced into 
the chamber. Due to the low Reynolds number (ܴ௘= 9.95) within the device, laminar flow 
was used for the simulation and the flow rate was set to 2 mL/min in accordance with 
previous experiments and simulations [81, 107]. 
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Figure 4.4 shows the simulation and trajectories of 100 super-paramagnetic beads 
flowing inside the dual-chamber system. According to the results, a uniform flow field was 
quickly established following the introduction of beads into the upper chamber. 
Subsequently, 52% of the beads ended up in the bottom chamber via the micro-aperture 
holes. This implied that, in order to aid in the visualization of cells in the upper chamber 
for actual experiments, a dual-magnet mode was going to be necessary. This allows any 
remaining free beads on the micro-aperture chip surface to move laterally, find a hole, and 
fall into the bottom chamber [81].  
 
Figure 4.4. Bead trajectory simulation results. (a) The flow field in the device with the inlet flow rate set to 2 mL/min. (b) Trajectories of magnetic beads in the dual-chamber system showing that 52% of the beads will fall through the micro-aperture holes during flow, indicating the need for a dual-magnet mode to aid in the removal of the remaining protein-bound beads and free beads that land on the chip surface. 
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4.3.2 Cell Detection in the Absence of Free PSMA 
Beads conjugated with various antibodies were used to characterize the ability of 
the micro-aperture device for detecting rare cells without free protein present. As 
LNCaP cells are known for expressing significant amounts of both PSMA and EpCAM 
surface markers, corresponding antibodies to these two antigens were initially investigated 
[117]. Using two quantities of magnetic beads (40 µg and 80µg) for each target, antibody 
bead conjugates were prepared and tested in order to achieve the highest cell detection 
yield. Captured cells were verified based on a combination of factors including their size 
(10-30 µm), shape (close to circular), and fluorescence signals, wherein anti-PSMA-PE (+), 
anti-CK-FITC (+) and DAPI (+) cells were scored as a positive result (Figure 4.5).  
 
Figure 4.5. Fluorescence images of LNCaP cells. Single cell (row 1), two cells (row 2), and three cells (row 3) were stained with anti-PSMA-PE, anti-CK-FITC, and DAPI to verify the identification of the LNCaP cells captured. 
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As shown in Figure 4.6 a, both quantities of anti-PSMA-only beads led to a 
detection yield of ~50% of the spiked LNCaP cells. For EpCAM, while the average 
capture value for 80 µg of beads was higher than that for 40 µg (96% versus 88%), 
from a statistical perspective, the difference was not significant (p > 0.05). The 
higher capture for EpCAM compared to PSMA correlates with a higher level of 
expression for the former, which was confirmed using a fluorescence cell-labeling 
assay (Figure 4.6 (b)). These results indicated a level of expression for EpCAM that 
was about twice that of PSMA. As the goal of this work was to achieve dual 
detection of LNCaP cells and free PSMA protein, a 50% mixture of anti-EpCAM 
and anti-PSMA bead conjugates was then tested (40 µg of each). The data revealed 
that this combination was able to achieve the same high yield (~94%) as compared 
to using only anti-EpCAM beads. Thus, the presence of anti-PSMA did not interfere 
with the capture efficiency. It should be noted that since LNCaP cells express both 
surface antigens, it is possible that both antibody beads play a role in cell capture, 
especially due to the heterogeneous nature of cell populations [118]. For example, a 
small number of cells within the population may express more PSMA than EpCAM. 
However, anti-EpCAM, due to being significantly more expressed overall, is likely 












In order to verify the specificity of PSMA and EpCAM ligands and to ensure that 
the antibody conjugated beads were not non-specifically capturing LNCaP cells, an 
antibody against one additional surface marker, epidermal growth factor receptor 
(EGFR), was tested as a negative control. Previous reports have indicated that 
LNCaP cells do not exhibit high levels of EGFR, which was also confirmed by our 
fluorescence staining experiments (Figure 4.6 (b)) [119]. The results shown in 
Figure 4.6 (a) for anti-EGFR conjugated beads provide further evidence that LNCaP 
cells express very little EGFR as only ~7% detection yield was achieved, for both 
amounts of beads tested.  
 To further validate the specificity of the PSMA and EpCAM antibody bead 
combination for our cellular targets, KB cells, a type of epithelial cancer cell line 
known for expressing high levels of folate receptor (FR) but no significant amounts 
of PSMA [120] or EpCAM (Figure 4.6 (c)), were used as an additional negative 
control. Compared to LNCaP cells, KB cells were found to be captured significantly 
less with the anti-PSMA and anti-EpCAM bead combination (95% versus 9% in 
Figure 4.6 (d)). This confirmed that the anti-PSMA and anti-EpCAM bead mixture 
is able to achieve high capture efficiency of cells that over-express specific surface 
antigens. It should be mentioned that 9% (instead of 0%) of KB cells were captured 
because KB, due to being epithelial in nature, expresses some amount of EpCAM 
on the cell surface [121].  
While a ~94% capture yield for LNCaP cells using a mixture of anti-PSMA and 
anti-EpCAM beads was achieved, there were still 6% which were not detected. Thus, 
we investigated whether these uncaptured cells passed through the micro-apertures 
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into the bottom chamber. Following the detection of LNCaP cells on the micro-
aperture chip surface, the bottom chamber was inspected using a bright-field 
microscope in order to observe the lower chamber surface (i.e. the transparent film) 
as well as the bottom of the micro-aperture holes – no cells were found. This 
indicates that the small number of uncaptured cells might have been lost due to the 
heterogeneous nature of the cell population, with several cells not expressing a 
sufficient amount of either PSMA or EpCAM antigen to enable a magnetic pull 
down to the micro-aperture surface. While expected to be minimal, it is also possible 
that some cells may have stuck to the walls of the sample tube or the tubing used in 
the fluidic system and hence may have been lost.  
4.3.3 Detection of Free PSMA in the Absence of LNCaP Cells 
Next, the ability of the micro-aperture device to detect free proteins in the absence 
of cells was evaluated. Using the same procedures and conditions as for cell 
detection, different concentrations of free PSMA (0 – 12.5 nM, 0 – 1000 ng/mL) 
were spiked into 1 mL of culture medium. The sample was then incubated with a 
50% mixture of anti-PSMA and anti-EpCAM beads. Following the capture and 
elution of protein-bead complexes and free beads from the lower chamber of the 
micro-aperture device, the retrieved beads were subsequently injected into a single 
chamber platform for fluorescence analysis. Figure 4.7 shows the fluorescence and 
corresponding bright field images of the beads distributed on the single chamber 
device glass surface for three different PSMA concentrations: 12.5 nM (1000 
ng/mL), 1.25 nM (100 ng/mL), and 0 nM (0 ng/mL). Using these images with 
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multiple PSMA spiked concentrations subsequently allowed the limit of detection 
(LOD) for the micro-aperture device to be determined. 
 
Figure 4.7. Three pairs of fluorescence (left) and bright-field (right) images collected from cell media samples spiked with PSMA concentrations of 12.5 nM (1000 ng/mL) (a), 1.25 nM (100 ng/mL) (b), and 0 nM (0 ng/mL) (c). 
In order to determine the numerical correlation between the input (PSMA concentration) 
and output (fluorescence) signals, we collected fluorescence images of the stained beads 
and the corresponding reversed bright-field image from the same observation window 
[107]. The fluorescence intensity was then normalized by the intensity of the reversed 
bright-field image, which was used as an estimation of the amount of beads in that 
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observation window. The normalized intensity, termed the “B-ratio”, thus represents the 
fluorescence signal per bead. The B-ratio was measured for eight different PSMA 
concentrations ranging from 0 to 12.5 nM (0 – 1000 ng/mL) as shown in Figure 4.8 (a). 
Performing a least squares Langmuir Isotherm fit to the experimental data revealed:  
B୰ = 0.222 + ଵ.଴଺ଵାଶ.ଽ଻ େ౦⁄                      (4.1) 
where ܤ௥ is the B-ratio; ܥ୔ is the PSMA concentration (nM); and 0.222 is the theoretical 
bias which is attributed to either non-specific binding between the fluorescent dye and 
antibody beads and/or the intrinsic fluorescence background of the magnetic beads. The 
theoretical bias agrees with our experimental B-ratio bias of 0.198, which was the observed 
response in the absence of PSMA. The intersection of the fitted curve with the background-
plus-three-standard-deviation line (Figure 4.8 (b)) corresponds to a PSMA spiked 
concentration of 34 pM (2.7 ng/mL), which we consider as the LOD for this assay 
using the new device. However, lower concentrations were still detectable (albeit 
not quantifiable based on our conservative definition of the LOD) using this assay. 
The effective dissociation constant (Kd) between anti-PSMA and PSMA was found to be 
approximately 3.0 nM, which is in reasonable agreement with previous reports [122, 123]. 
While the simplicity of the overall method allowed an intensity assay using a fluorescence 
microscope to be used to quantify free-protein capture, the ability to easily retrieve the 
beads using the new device also enables the future use of other analytical techniques (e.g. 






Figure 4.8. (a) The standard detection curve for free-PSMA spiked into cell culture media using the anti-PSMA and anti-EpCAM bead mixture. The horizontal brown line represents the experimental background (B-ratio when PSMA = 0 nM) and the green line represents the background plus three standard deviations. The data reveals a limit of detection of 34 pM. Error bars indicate one standard deviation from three experiments for each concentration. (b) Detection limit of PSMA spiked into culture media in the absence of LNCaP cells. 
As different combinations and amounts of antibody beads were analyzed to achieve the 
highest cell detection yield, we also investigated the contribution of anti-PSMA and anti-
EpCAM for binding free PSMA. Here, various antibody bead combinations (80 µg of anti-
EpCAM only, 80 µg of anti-PSMA only, and 40 µg of anti-EpCAM plus 40 µg of anti-






Figure 4.9. B-ratios of different combinations of antibody beads (anti-EpCAM, anti-PSMA plus anti-EpCAM, and anti-PSMA) for detecting multiple concentrations of PSMA (0 - 12.5 nM) spiked into culture media.  
The results showed that anti-PSMA alone achieved the highest recovery, followed by the 
mixture of antibody beads. The use of only anti-EpCAM was found to have no significant 
effect on the ability to capture PSMA. While using only anti-PSMA beads would possibly 
allow for an improvement in the LOD for spiked PSMA, this would come at a loss in cell 
detection yield (Figure 4.6 (a)). Thus, in order to achieve the highest yield for dual detection 
of cells and PSMA, a 50% bead mixture of anti-PSMA and anti-EpCAM beads was used 
for the remainder of this work. However, increasing the micro-aperture array area to 
accommodate an even larger number of beads, in a future device design, may lead to 
improved LODs for molecular targets while maintaining high cell capture efficiencies. 
4.3.4 Dual Detection of LNCaP Cells and Free PSMA Spiked into Media 
Next, the capability of the micro-aperture chip system for separating and detecting 
both LNCaP cells and free-PSMA from a single solution was tested. For these 
experiments, ~100 LNCaP cells and various concentrations (0 - 12.5 nM, 0 – 1000 
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ng/mL) of PSMA were spiked into culture medium (1 mL). The cell quantity and 
protein concentrations were chosen to be comparable to values reported for healthy 
human controls (PSMA only: 1 – 600 ng/mL (16 pM – 7.5 nM)) and prostate cancer 
patients (PSMA: 350 – 950 ng/mL (4.38 – 11.9 nM) and CTCs: 0 – 400 per mL of whole 
blood) [23, 80, 124-126]. Figure 4.9 shows the measured PSMA concentration 
determined by Equation (4.1) (left y-axis) and the percentage of LNCaP cells 
captured (right y-axis) as a function of the PSMA concentration spiked into the 
media (x-axis). These results reveal several features. First, for PSMA spiked 
concentrations from 125 pM to 12.5 nM, the spiked concentrations (x-axis) and the 
measured concentrations (left y-axis) matched almost perfectly. However, the next 
lowest spiked condition (12.5 pM) was slightly above the measured value as 
determined from Equation (4.1). This is likely due to the low resolution in the 
detection curve at these spiked concentrations and indicates that our conservative 
method to define the LOD (34 pM) as being three standard deviations from the 
baseline noise, is reasonable. For the lowest concentration analysed (1.25 pM) in 
this particular set of experiments, the measured PSMA value did not significantly 
differ from the background response (0 nM). Most importantly, for all samples tested, 
the micro-aperture device was able to detect LNCaP cells with a yield of ~93%.  
The results from Figure 4.10 confirm that the new device can detect multiple 
concentrations of PSMA while also capturing LNCaP cells. Furthermore, they also 
indicate that the cell detection yield is not significantly affected by the presence of 
free-PSMA. One possible reason, as mentioned above, is that the anti-EpCAM beads 
play the dominant role in capturing a majority of the cells. The anti-PSMA beads 
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thus play the major role in PSMA protein detection with a secondary benefit of 
helping anti-EpCAM in capturing more cells. As an additional check, the micro-
aperture system was further characterized by simultaneously detecting a single 
concentration of PSMA (1.25 nM) in the presence of a variable number of LNCaP cells (0 
– 80) using the anti-PSMA and anti-EpCAM bead mixture. Subsequent fluorescence 
analysis showed that the ability to capture free protein biomarkers was not significantly 
affected by the number of target cells present (Figure 4.11).  
 




Figure 4.11. Measured PSMA concentrations (using Equation (4.1)) which were concurrently detected from culture media samples containing different numbers of spiked LNCaP cells and 1.25 nM of added PSMA. 
4.3.5 Dual Detection of LNCaP Cells and Free PSMA Spiked into Healthy Human 
Blood 
In order to demonstrate the potential of the micro-aperture system for the simultaneous 
detection of cell and protein targets from clinical samples, LNCaP cells and PSMA were 
spiked into diluted healthy human blood which was used to simulate an actual prostate 
cancer patient. For these experiments, 250 µL of unprocessed whole blood was first diluted 
to 1 mL with PBS and then spiked with LNCaP cells and/or free-PSMA, in addition to the 
level of PSMA naturally present. The sample was then incubated using the 50% mixture 
of anti-PSMA and anti-EpCAM beads, injected into the micro-aperture device, and 
analyzed using similar procedures as above. The measured PSMA concentration was 
calculated using Equation (4.1). LNCaP cells were verified based on a combination of 
factors including their size (10-30 µm), shape (close to circular), and fluorescent signals, 
wherein anti-CK-FITC (+), anti-CD45-PE (-) and DAPI (+) cells were scored as a positive 
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result. Anti-CD45-PE (+) and DAPI (+) cells were identified as white blood cells (WBCs). 
Example images are shown in Figure 4.12. 
 
Figure 4.12. Fluorescence images of captured cells. (a) LNCaP cells were first identified with anti-CK-FITC (green) and white blood cells were identified with anti-CD45-PE (red). (b) Cell nuclei were stained with DAPI. (c) Shows the merged image of panels (a) and (b). Images were artificially enhanced for clarity. 
For these experiments, four different conditions were tested (Figure 4.13) using the 
diluted blood sample. The first condition (Group 1) involved spiking ~54 LNCaP cells and 
1.25 nM (100 ng/mL) of PSMA. Group 2 represents a sample containing ~27 spiked 
LNCaP cells and 50 pM (4 ng/mL) of spiked PSMA. Group 3 contained only ~27 LNCaP 
cells. Group 4 was used as a control containing no added target protein or added cells. It 
should be noted that the spiked PSMA concentrations provided are relative to the 1 mL 
diluted sample volume.  
The results shown in Figure 4.13 reveal several important features of the new device. 
First, for all conditions where LNCaP cells were added, a consistent detection efficiency 
of ~90% was obtained. This was true for both quantities of cells (i.e. 27 and 54 cells per 1 
mL of diluted blood) as well as both concentrations of spiked PSMA (i.e. 50 pM and 1.25 
nM) and is not significantly different from that achieved using culture media (~93%). The 
zero detected cells in the control samples (Group 4) further indicates that the increased 
captured cell purity (i.e. the enhanced visualization of cells), due to the separation of 
110 
 
protein-bound beads and free-beads afforded by the micro-aperture chip, led to the 
elimination of any false-positive results. However, ~200 WBCs were also observed on the 
micro-aperture chip surface after each detection. This is likely the result of non-specific 
binding of WBCs via three mechanisms: (1) WBCs from blood adhering to the chip surface. 
(2) WBCs non-specifically binding to the magnetic beads in blood during incubation which 
are then attracted to the chip surface. (3) WBCs expressing small amounts of surface 
antigens and are thus captured by the anti-beads. To put this observation into perspective, 
using a conservative estimate, 250 µL of whole blood contains over ~1 million WBCs 
[127]. Thus, the device was able to remove more than 99.9% of endogenous leukocytes. 
For PSMA, the measured concentration for Group 3 and Group 4 were nearly identical 
(both were approximately 0.39 nM (31 ng/mL)) which revealed that the presence and 
capture of LNCaP cells did not interfere with free-protein detection. The 0.39 nM measured 
PSMA concentration for the diluted sample is also consistent with previous studies using 
healthy human blood [125, 126]. Spiking a PSMA concentration of 50 pM into the diluted 
sample (Group 2) was found to be significantly different from the PSMA measured 
concentrations for Groups 3 and 4 (p < 0.05). This appears to represent the lowest 
detectable concentration above background using this device coupled with the fluorescence 
quantification method utilized in this work. The lowest detectable concentration from 
diluted blood (50 pM) in Figure 4.13 is larger than the lowest detectable concentration from 
culture media in Figure 4.10 (12.5 pM). The difference in sensitivities is likely due to 
matrix affects (e.g. non-specific binding) which usually increases the background noise of 
the assay. However, this did not appear to affect cell capture yields. Lastly, the difference 
in the measured concentration of PSMA from Group 1 compared to Groups 3 and 4 (a 
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difference of 1.31 nM) is similar to the theoretical difference in the spiked concentration 
(1.25 nM). This indicates that higher concentrations of target protein are still efficiently 
captured even when simultaneously detecting cells.  
 
Figure 4.13. The detection yield of LNCaP cells and the measured concentration of free-PSMA obtained from diluted healthy human blood (1:3, Blood:PBS). Grey columns represent the cell detection yield while the orange columns represent the measured PSMA concentration as determined from Equation (4.1). Zero cells were detected for Group 4. The number of LNCaP cells spiked in Groups 1, 2, 3, and 4 were approximately 57, 27, 27, and zero, respectively. The concentrations of PSMA spiked in Groups 1, 2, 3, and 4 were 1.25 nM, 50 pM, 0 nM, and 0 nM, respectively. Error bars indicate one standard deviation for three measurements. 
While the quantity of spiked LNCaP cells analyzed in Figure 4.13 falls into the expected 
numbers of CTCs observed in prostate cancer patients (0 – 400 CTCs per mL of whole 
blood), we also challenged the new device by performing dual detection at the lower end 
of this range. In order to detect (and accurately aliquot) a small number of target cells using 
conditions as similar as possible to that in Figure 4.13, a larger volume of blood was 
necessary. Here, 1 mL of whole blood was diluted with PBS (to 4 mL), spiked with ~20 
112 
 
LNCaP cells and 50 pM of PSMA, and then incubated on an end-over-end rotator to 
homogenize the sample. The solution was then split into 4 – 1 mL tubes and each was 
individually analyzed as above. A control sample without added PSMA or target cells was 
also tested. The results revealed that the number of LNCaP cells captured in consecutive 
tubes was 4, 6, 4, and 3 cells, which compared to zero cells detected in the control – the 
theoretically expected result was 5 cells per tube. Due to the stochastic distribution of a 
small number of cells in the 4 mL sample, the capture yield was calculated by summing 
the four individual tubes, revealing an 85% detection efficiency. For free-PSMA, the 
concentration in the four tubes was uniformly distributed and was significantly different 
from the non-spiked control (a difference of ~80 pM, consistent with Figure 4.13). 
Collectively, these results show the great potential of the micro-aperture device for dual 
detection of cell and protein targets from clinical samples.  
4.4 Conclusions 
In Chapter 4, we presented a dual-chamber, immuno-magnetic device capable of 
the simultaneous detection of cellular and molecular biomarkers of prostate cancer. 
The micro-aperture chip design provided affinity- and size-based separation of 
targets while enabling highly efficient capture of cells and proteins from a single 
sample fluid. The new platform yields cells in greater purity (i.e. the elimination of 
protein-bound or free magnetic beads), improves multi-ligand targeting by allowing 
for higher bead concentrations to be used in an assay, and enables further 
downstream analysis of captured analytes. Two types of prostate cancer biomarkers, 
free-PSMA protein and LNCaP cells, were measured and used to characterize the 
device. The results demonstrated a 34 pM LOD of PSMA spiked into culture media. 
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The detection yield of LNCaP cells was found to be independent of the PSMA 
concentration using a mixture of antibody beads against different cell markers, and 
to be consistently near ~93%. The dual measurement of PSMA and LNCaP cells 
was further demonstrated from diluted healthy human blood to mimic an actual 
cancer patient sample. For these experiments, the cell detection yield was 85 – 90%, 
independent of the spiked PSMA concentration. The lowest detectable PSMA 
amount was found to be 50 pM for the diluted blood sample. The capability to 
simultaneously detect protein and cellular targets combined with the ability to extract 
desired rare cells for further investigation illustrates the potential of this device for high-
throughput analysis of clinical samples. In the future, we expect this system to be highly 





CHAPTER 5. APPLICATIONS AND FUTURE WORK 
5.1 Introduction 
The previous chapters have introduced and demonstrated the performance of two 
generations of a fluidic system capable of simultaneously detecting molecular and cellular 
biomarkers. The significance of the second-generation platform for application in the clinic 
was initially presented (Chapter 3) as a means of sensitively detecting and quantifying 
CTCs in NSCLC and PANC blood samples. In this chapter, we extend the potential of our 
device by further showing its ability to cultivate captured tumor cells. Future work will 
then focus on utilizing the isolated CTCs for downstream single-cell genetic analysis and 
mutation identification, the advancement and implementation of novel capture ligands 
(aside from antibodies) for improving assay performance, and correlating captured CTCs 
with specific protein biomarkers in actual patient samples. These applications demonstrate 
the ability of the micro-chip system to integrate the simultaneous and sensitive detection 
of multiple biomarkers (cells and proteins/molecules), which can be used for monitoring 
cancer treatment, with advanced single-cell analysis techniques and biomarker discovery. 
5.2 Post-detection Application: Cultivation of Captured Cells 
While the ability to utilize the second-generation platform for achieving high 
volumetric blood sample through-put and the sensitive capture of CTCs from patient 
blood is important in and of itself, the capability to further cultivate these captured 
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CTCs would provide additional and valuable information about the disease – such 
as the response to certain cancer drug treatment regimens. However, this requires 
not only sensitive cellular detection but also the subsequent ability to release the 
captured cells as viable analytes for downstream culturing. In order to demonstrate 
this potential, preliminary experiments were conducted.  
Here, tumor cells (~100 MCF-7 cells) were first spiked into culture media (1 mL) 
and then captured with the device (see Chapter 3 for procedural details). Following 
detection and the elimination of free beads from the chip surface, the bottom magnet 
was removed and the subsequent injection of PBS allowed the captured cells to be 
collected at the pump outlet, in a petri dish. A bright-field image of the retrieved 
cells is shown in Figure 5.1 (a). While this ability to easily obtain the captured cells 
from the device allows one to perform numerous types of analyses, such as cell 
enrichment or DNA/RNA isolation, we chose to investigate the susceptibility of the 
cells in culture. Thus, the growth of the cells in an incubator was monitored over 
several days and is shown in Figure 5.1 (b-e). Initially, the results revealed that the 
bead-bound cells first settled down and attached to the petri dish surface on day 0. 
However, from day 1 onwards, the cells began to grow and divide – an indication of 
their viability – with a morphology that was similar to that of the parental cell line 
prior to the experiment. A follow up experiment conducted using captured KB cells 




Figure 5.1. Post-detection retrieval and growth of MCF-7 cells. (a) Cells retrieved from the micro-aperture chip and placed in a petri dish. (b)–(e) Cell growth from day 1 to day 5. 
This preliminary evidence suggests that the use of antibody conjugated beads with 
the micro-chip device for the capture of rare tumor cells has the potential for 
enabling their release and subsequent cultivation under suitable environmental 
conditions. However, additional characterization will be necessary to further verify 
that the growth of the captured cells is similar to the parental line, from a molecular 
level. As CTCs are such a rare occurrence in a patient blood sample, the feasibility 
and reproducibility for cultivating single cells or small numbers of cells will also be 
investigated.  
5.3 Future Work 
5.3.1 Single Cell Analysis 
As the ability to grow cultures of captured cells is desirable, an additional advantage of 
whole cell detection enabled by the second-generation device is the ability to perform other 
117 
 
types of downstream assays using only single-cells. For example, a captured cell can be 
aspirated from the device, lysed, and then subjected to high-throughput DNA/RNA 
sequencing to obtain valuable information. This includes the discovery of genetic 
mutations which could then be translated to the clinic as a novel biomarker, the elucidation 
of intrinsic tumor biology, and providing new targets to aid in the development of 
therapeutics. In a recent study by Chen et al. involving single CTC analysis, the authors 
found that captured tumor cells that express genes relate to the epithelial–mesenchymal 
transition are strong predictors of metastatic prostate cancer [128]. This illustrates the 
potential value of the information that can be uncovered via the deeper examination of 
captured CTCs enabled using our device. 
While advances in high-throughput DNA/RNA sequencing enable one to obtain whole-
genome level information from a small number of cells, it has a high requirement: the 
captured cells need to be as pure as possible and should be devoid of endogenous 
analytes/cells present in the original blood sample. While the second-generation platform 
enables more than 99.9% of WBCs to be removed when capturing the rare CTCs on the 
chip surface, the small number of remaining normal cells constitute a background that 
makes it difficult to extract genomic information from the few tumor cells present. In order 
to meet this high requirement and achieve single-cell level DNA/RNA analysis using the 
micro-chip device, we plan to first perform a round of CTC isolation and then follow-up 
this process with single-cell aspiration as demonstrated in Figure 5.2 using a micro-pipette 
to selectively withdraw a single-cell and move it to a collection tube. The retrieved and 
processed cells will be delivered to our collaborators, cancer biologists and clinical 
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oncologists at the Indiana University Medical School, who will work with us to explore 
the genetic analysis of captured single tumor cells from cancer patient samples. 
 
Figure 5.2. Schematic for single-cell CTC analysis using the micro-chip device. (a) Detected cells are first washed out of the device and onto an exposed surface. (b) Single-cells are then selectively isolated using a micro-pipette and placed into a collection tube for downstream genetic analysis (c).  
5.3.2 Integration of Novel Ligands for CTC Detection  
As mentioned throughout this thesis, the use of antibody conjugated magnetic beads with 
the two generations of devices enabled high efficiency capture of target analytes – cells 
and molecules. However, while antibodies have many positive attributes, such high 
specificity and affinity constants, the use of protein capture agents also has several 
disadvantages. These include variability associated with immobilization (e.g. 
biotinylation), high cost, as well as being prone to denaturation, among others [129]. For 
these reasons, there has been a push to develop cheaper and more stable targeting ligands 
which can simultaneously achieve similar levels of specificity and binding kinetics [64]. 
As the micro-chip device is ideally suited for rapidly analyzing large volumes of samples 
incubated with ligand conjugated magnetic beads, the investigation of alternative 
molecules which target many different biomarkers (i.e. multiple cell surface receptors 
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and/or free-protein molecules) can be easily conducted. We currently have an ongoing 
collaboration with Prof. Phillip Low’s group at Purdue University in which we are testing 
the feasibility of applying newly synthesized small-molecule targeting compounds for 
capturing folate+ tumor cells. We plan to continue this work and soon apply the outcome 
to CTC detection from ovarian cancer patients while using the captured cells for testing 
novel therapeutics in vitro. 
5.3.3 Patient Blood Test 
Lastly, as our device represents a unique ability for high-throughput sample analysis and 
sensitive CTC detection, we plan to continue our collaboration with multiple research labs 
at the Indiana University Medical School for the detection of tumor cells from cancer 
patient samples. This will help to better understand the correlation between CTC count and 
a patient’s disease state or treatment progression.  
Additionally, we also demonstrated the ability to simultaneously detect cellular and 
molecular biomarkers from a single sample. This is important for aiding the development 
of new biomarker panels that can provide a more specific and accurate patient diagnosis – 
based on a combination of large (e.g. cells) and small (protein) target analytes – as well as 
to help uncover new mechanisms of the underlying biology of a disease. A good example 
of this limitation involves the over reliance in prostate cancer diagnosis on the 
concentration of only measured PSA levels in blood – an analysis which could be made 
more reliable by simultaneously detecting CTCs and regularly monitoring the observed 





As cancer has been shown to be increasingly heterogeneous, the ability to perform 
multiplexed analysis of biomarkers has become ever more important in the diagnosis of a 
patient’s disease state. In this thesis, we presented two generations of devices which 
enabled us to achieve the concurrent detection of both cellular and molecular target 
analytes from a single blood sample. In the development of the first-generation system 
(Chapter 2), a single chamber fluidic device captured and quantified both large (cells) and 
small (free-proteins) targets on the same detection surface. This platform subsequently 
enabled the simultaneous detection of two analytes using ascites fluid from an ovarian 
cancer patient. While this first-generation device achieved the capability of concurrent 
detection, it suffered from the inability to measure the large and small targets without 
mutual interference, while also limiting the number of antibody beads which could be used 
in an experiment – an important experimental condition for achieving highly efficient 
capture of extremely rare target cells. 
In order to further improve the performance of the dual detection modality, we designed 
a second-generation device which could physically size-separate cellular and molecular 
targets into upper and lower chambers, respectively, via the use of a silicon chip containing 
micro-apertures (Chapters 3 and 4). This system enhances the captured cell purity, allows 
the separate retrieval of captured cells and proteins for downstream analysis, and enables 
higher bead concentrations for improved multiplexed ligand targeting. By initially focusing 
on only CTC capture, the second-generation device was applied to the successful detection 
and enumeration of CTCs from blood samples of cancer patients and demonstrated the 
ability to correlate cancer treatment with tumor cell count. In Chapter 4, we demonstrated 
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the dual detection capability of the micro-aperture chip system by simultaneously detection 
two targets spiked into healthy human blood, thus illustrating its clinical potential.  
A key benefit of the second-generation system involves the ability to retrieve detected 
target cells for downstream analysis. Thus, we were able to demonstrate this feature and 
show the viability of captured cells by successfully culturing them off-chip. Future work 
will involve working with collaborators to perform genetic analysis for mutation 
identification using CTC single-cells detected from cancer patients, to develop and validate 
novel targeting ligands (as a replacement for antibodies), and to aid in the development of 
new biomarker panels. Due to its versatility, robustness, relative architectural simplicity, 
and compatibility with existing practices, we envision the second-generation platform to 
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MATLAB codes for B-ratio calculation 
clear all; clc;  
%file path set  
cd('FLIE PATH');  %get fluorescent image file [file_name,file_path] = uigetfile('*.jpg', 'Pick a FL file' I = imread([file_path, file_name]);  
%convert RGB image to Gray scale and save as a M*N matrix tg1 = I(:,:,2);  %get the size of entire pic [width length] = size(tg1);  %sub window re_point_s = [101 101]; re_point_e = [width-100 length-100];  
%caculate the total intensity of FL g = uint8(zeros(re_point_e(1)-re_point_s(1)+1, re_point_e(2)-re_point_s(2)+1)); r = tg1(re_point_s(1):re_point_e(1), re_point_s(2):re_point_e(2)); b = uint8(zeros(re_point_e(1)-re_point_s(1)+1, re_point_e(2)-re_point_s(2)+1)); c1 = sum(r(:));  
%save processed FL image imwrite(r, ['FL_gray_',file_name]);  
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